Refine
Year of publication
- 2019 (576) (remove)
Document Type
- Article (500)
- Doctoral Thesis (42)
- Preprint (19)
- Part of Periodical (8)
- Book (4)
- Contribution to a Periodical (3)
Has Fulltext
- yes (576)
Is part of the Bibliography
- no (576)
Keywords
- inflammation (10)
- glioblastoma (8)
- cancer (7)
- Breast cancer (6)
- biomarker (6)
- Inflammation (5)
- breast cancer (5)
- immunotherapy (5)
- mTOR (5)
- Biomarkers (4)
- Chemotherapy (4)
- Gene expression (4)
- Human behaviour (4)
- Oncology (4)
- Outcome (4)
- autophagy (4)
- cirrhosis (4)
- fMRI (4)
- glioma (4)
- hypoxia (4)
- infection (4)
- invasion (4)
- macrophage (4)
- microRNA (4)
- mitochondria (4)
- Aortic valve (3)
- Cancer treatment (3)
- Children (3)
- Cirrhosis (3)
- Death rates (3)
- Depression (3)
- Drug therapy (3)
- Germany (3)
- HDAC (3)
- Hemorrhage (3)
- Hepatitis C (3)
- Immunotherapy (3)
- Mental health and psychiatry (3)
- Molecular neuroscience (3)
- Multivariate analysis (3)
- Neutropenia (3)
- Predictive markers (3)
- Prognosis (3)
- Prävention (3)
- Quality of life (3)
- Research article (3)
- T cells (3)
- acute coronary syndrome (3)
- angiogenesis (3)
- complications (3)
- cytokines (3)
- differentiation (3)
- efficacy (3)
- epilepsy (3)
- integrin (3)
- leukemia (3)
- macrophage polarization (3)
- macrophages (3)
- monocytes (3)
- mycophenolic acid (3)
- neoadjuvant therapy (3)
- p21 (3)
- particulate matter (3)
- peripheral artery disease (3)
- prevention (3)
- reactive oxygen species (3)
- risk factors (3)
- sepsis (3)
- surgery (3)
- tumor microenvironment (3)
- vitamin D (3)
- Acute inflammation (2)
- Acute myeloid leukemia (2)
- Adverse events (2)
- Age groups (2)
- Alpelisib (2)
- Apoptosis (2)
- Aspergillus fumigatus (2)
- Ataxia telangiectasia (2)
- Atezolizumab (2)
- B cells (2)
- Biomarker (2)
- Body mass index (2)
- CAD/CAM (2)
- CC16 (2)
- CDKN1A (2)
- CIK cells (2)
- Cancer (2)
- Cancer chemotherapy (2)
- Cancer genomics (2)
- Cardiac hypertrophy (2)
- Cell differentiation (2)
- Cell proliferation (2)
- Clinical presentation (2)
- Cognition (2)
- Community health services (2)
- Crohn’s disease (2)
- Cytokines (2)
- DMEK (2)
- DNA methylation (2)
- Developmental biology (2)
- Diagnostic medicine (2)
- Digestive system procedures (2)
- EGFR (2)
- Ears (2)
- Ejection fraction (2)
- Endothelial cells (2)
- Epidemiology (2)
- Fatty liver (2)
- HBV (2)
- HSV (2)
- Heart (2)
- Heart failure (2)
- Hepatitis B (2)
- Hepatitis C virus (2)
- Hospitals (2)
- Hypertension (2)
- IBD (2)
- Incidence (2)
- Infectious diseases (2)
- Inflammatory diseases (2)
- Ischemia (2)
- Katherine (2)
- Knowledge (2)
- Liver diseases (2)
- MYC (2)
- Machine learning (2)
- Macrophages (2)
- Magnetic resonance imaging (2)
- Malaria prevalence (2)
- Mammakarzinom (2)
- Mesenchymal stem cells (2)
- Messenger RNA (2)
- Metastasen (2)
- Molecular medicine (2)
- Mouse (2)
- Multivariable analysis (2)
- NADPH oxidase (2)
- Obesity (2)
- Ophthalmology (2)
- Outcomes (2)
- PARP (2)
- PD-L1 (2)
- PD‑L1 (2)
- PI3K (2)
- Patients (2)
- Pediatric infections (2)
- Personalized medicine (2)
- Pregnancy (2)
- Psychiatric disorders (2)
- RITA (2)
- Radiomics (2)
- Sepsis (2)
- Sleep (2)
- Social epidemiology (2)
- Social health determinants (2)
- Stroke (2)
- Suicide (2)
- Supportivtherapie (2)
- Surgery (2)
- Surgical and invasive medical procedures (2)
- Surgical oncology (2)
- Transcription factors (2)
- Treatment (2)
- T‑DM1 (2)
- additives (2)
- adjuvant therapy (2)
- adjuvante Therapie (2)
- advanced (2)
- aged (2)
- alirocumab (2)
- alpelisib (2)
- antiviral therapy (2)
- apoptosis (2)
- arteriogenesis (2)
- astrocytes (2)
- atezolizumab (2)
- attention (2)
- bone metabolism (2)
- brain metastases (2)
- caspase-2 (2)
- cholesterol (2)
- chronic kidney disease (2)
- classical Hodgkin lymphoma (2)
- cognition (2)
- colorectal cancer (2)
- complement (2)
- corneal edema (2)
- corneal transplantation (2)
- curcumin (2)
- cyclosporin A (2)
- cytomegalovirus (2)
- data science (2)
- dementia (2)
- dental implant (2)
- depression (2)
- early breast cancer (2)
- echocardiography (2)
- eicosanoids (2)
- electrolytic cleaning (2)
- environmental tobacco smoke (2)
- extracellular matrix (2)
- fortgeschritten (2)
- frühes Mammakarzinom (2)
- graph theory (2)
- heart failure (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- hippocampus (2)
- human (2)
- immune evasion (2)
- innate immunity (2)
- integrins (2)
- liver disease (2)
- lncRNA (2)
- magnetic resonance imaging (2)
- metabolic syndrome (2)
- metastatic (2)
- methylprednisolone (2)
- migration (2)
- modularity (2)
- mortality (2)
- multiple sclerosis (2)
- music (2)
- neoadjuvante Therapie (2)
- obesity (2)
- osteoporosis (2)
- periimplantitis (2)
- pharmacovigilance (2)
- phosphorylation (2)
- portal hypertension (2)
- primary care (2)
- primary health care (2)
- proliferation (2)
- prostaglandins (2)
- prostate cancer (2)
- proteome (2)
- proteomics (2)
- psoriasis (2)
- quantitative MRI (2)
- radical prostatectomy (2)
- radiotherapy (2)
- registry (2)
- renal function (2)
- secretome (2)
- signal transduction (2)
- sphingosine-1-phosphate (2)
- supportive therapy (2)
- targeted therapy (2)
- transplantation (2)
- trauma (2)
- tumor-associated macrophages (2)
- uteroglobin (2)
- (novel) brominated flame retardants ((N)BFR) (1)
- (surface) partial differential equations (1)
- 15-PGDH (1)
- 3Cs technology (1)
- 3D spatiotemporal resolved mathematical models (1)
- 3D tissue models (1)
- 3years (1)
- 5' UTR (1)
- 6-Schritt-Methode (1)
- A375 human melanoma cell line (1)
- AB-serum (1)
- ACL (1)
- ACLF (1)
- AICAR (1)
- AIS (1)
- ALF (1)
- AMD3100 (1)
- AML (1)
- AMPK (1)
- APRI (1)
- ASCT (1)
- AT-101 (1)
- ATG4 (1)
- ATG8 (1)
- ATM (1)
- ATO (1)
- AVM hemorrhage (1)
- Abdominal surgery (1)
- Abdominal trauma (1)
- Abiraterone acetate (1)
- Actinomycin D (1)
- Action potential (1)
- Addison’s disease (1)
- Adenocarcinoma (1)
- Adhesins (1)
- Adhesion (1)
- Adipose-derived mesenchymal stem cells (1)
- Adjustment of dosage at steady state (1)
- Adolescents (1)
- Agoraphobia (1)
- Akaike information criterion (AIC) (1)
- Akutes Koronarsyndrom (1)
- Alleles (1)
- Allergen immunotherapy (1)
- Allergoid (1)
- Aminotransferases (1)
- Anemia (1)
- Anesthesia, Intravenous (1)
- Aneurysmal subarachnoid hemorrhage (1)
- Aneurysms (1)
- Angiogenesis (1)
- Angiography (1)
- Anosmia (1)
- Antibody isotypes (1)
- Anticoagulants [MeSH] (1)
- Anticoagulation (1)
- Antigen-presenting cells (1)
- Antigens (1)
- Antiplatelet therapy (1)
- Antireflux surgery (1)
- Antiviral therapy (1)
- Anura (1)
- Aortic aneurysm (1)
- Aortic arch replacement (1)
- Aortic dissection (1)
- Aortic stenosis (1)
- Aortic stiffness (1)
- Aortic valve replacement (1)
- Aortic valve sparing (1)
- Apes (1)
- Arabin pessary (1)
- Arabin-Pessar (1)
- ArchT (1)
- Aromatase Inhibitors (1)
- Arrhythmia (1)
- Artificial intelligence (1)
- Aspergillus species (1)
- Asphyxia (1)
- Atelopus carbonerensis (1)
- Atelopus mucubajiensis (1)
- Atelopus tamaense (1)
- Atrial fibrillation (1)
- Attention (1)
- Attitude (1)
- Audio equipment (1)
- Audio signal processing (1)
- Audiology (1)
- Aurora A (1)
- Aurora Ax (1)
- Australia (1)
- Austria (1)
- Automated sRNA analysis (1)
- Autophagy (1)
- Awareness (1)
- Axon (1)
- B cell malignancies (1)
- B cell precursor acute lymphoblastic leukemia (1)
- B-cell antigen receptor (1)
- BBB (1)
- BCL2 (1)
- BI1361849 (1)
- BIAM switch assay (1)
- BMAC (1)
- BNC2 (1)
- BRAF mutation (1)
- Back pain (1)
- Bartonella (1)
- Biliary tree (1)
- Bilirubin (1)
- Bioelektrische Impedanzanalyse (1)
- Biomarkers & Diagnostic Imaging (1)
- Biotechnology (1)
- Bipolar disorder (1)
- Blood (1)
- Blood groups (1)
- Blood plasma (1)
- Blood pressure (1)
- Blood-brain barrier (1)
- BluePrint (1)
- Body-contouring surgery (1)
- Bone marrow (1)
- Bone marrow aspirate concentrate (1)
- Bone marrow aspiration (1)
- Bone strength assessment (1)
- Borrelia (1)
- Brain metastasis (1)
- Breast neoplasms (1)
- Breast tumors (1)
- Bufonidae (1)
- Burst (1)
- C-reactive protein (1)
- C-reactive proteins (1)
- C1 esterase inhibitor (human) (1)
- C1-esterase inhibitor protein (1)
- C3M (1)
- C4M (1)
- CAM (1)
- CD271 (1)
- CD3/CD19 depletion (1)
- CD36 (1)
- CD45RA naïve lymphocytes (1)
- CD8+ T lymphocytes (1)
- CD8+ tumor infiltrating lymphocytes (1)
- CHA2DS2-VASc-score (1)
- CHIP (1)
- CLP (1)
- CMV (1)
- CREB inhibitor (1)
- CRISPR/Cas (1)
- CRM (1)
- CRT-D (1)
- CTLA-4 (1)
- CV9202 (1)
- CVD biomarker (1)
- CVID (1)
- CWS Studiengruppe (1)
- CXCL12 (1)
- Caco-2 cells (1)
- Canada (1)
- Cancer detection and diagnosis (1)
- Cancer epidemiology (1)
- Cancer genetics (1)
- Cancer risk factors (1)
- Cancer therapeutic resistance (1)
- Cannabis (1)
- Carcinoma, Ductal, Breast (1)
- Cardiac device therapy (1)
- Cardiac monitoring (1)
- Cardiac necroenzymes (1)
- Cardiac remodelling (1)
- Cardiology (1)
- Cardiovascular Magnetic Resonance (CMR) (1)
- Cardiovascular epidemiology (1)
- Case management [MeSH] (1)
- Cell binding (1)
- Cell biology (1)
- Cell motility (1)
- Cell therapy (1)
- Cellular stress responses (1)
- Center-specific time in therapeutic range (cTTR) (1)
- Central nervous system metastases (1)
- Cerebral toxoplasmosis HIV (1)
- Cerebral vasospasm (1)
- Cesarean section (1)
- Chaperone (1)
- Chemical company (1)
- Chemoprevention (1)
- Chemosensitivity (1)
- Chlorides (1)
- Cholesterin (1)
- Chromatin accessibility (1)
- Chronic disease [MeSH] (1)
- Chronic health condition (1)
- Chronic hepatitis (1)
- Chronic hepatitis C virus (1)
- Chronic kidney disease (1)
- Chronic obstructive pulmonary disease (1)
- Cisplatinresistenz (1)
- Citation analysis (1)
- Clincial pharmacology (1)
- Clinical effectiveness (1)
- Clinical pathways (1)
- Clinical studies (1)
- Clinical trial (1)
- Clostridioides difficile (1)
- Cognitive impairment (1)
- Cognitive neuroscience (1)
- Cognitive psychology (1)
- Colchicum (1)
- Collagen (1)
- Collagens (1)
- Colloids (1)
- Colorectal cancer (1)
- Combined immune checkpoint blockade (1)
- Community based intervention (1)
- Comparative analysis (1)
- Complement cascade (1)
- Complication management (1)
- Comprehensive cancer centers (1)
- Computational biology and bioinformatics (1)
- Computational model (1)
- Computational sRNA analysis (1)
- Conduct disorder (1)
- Congenital duodenal obstruction (1)
- Contrast-enhanced (1)
- Cornea (1)
- Coronary heart disease (1)
- Cost-effectiveness (1)
- Cost-effectiveness analysis (1)
- Costs (1)
- Crispr/Cas (1)
- Cross-frequency coupling (1)
- Cross-sectional study (1)
- Cumulative dose (1)
- Cure (1)
- Curvilinear dose response (1)
- Cytochrome P450 enzymes (1)
- Cytogenetics (1)
- Cytoplasm (1)
- Cytoplasmic staining (1)
- Cytoskeletal proteins (1)
- Cytoskeleton (1)
- C‐reactive protein (1)
- DDA (1)
- DDIT4 (1)
- DHA (1)
- DILI (1)
- DME (1)
- DNA damage (1)
- DNA damage response (1)
- DNA repair (1)
- DNA-binding proteins (1)
- DNase1-seq (1)
- DSAEK (1)
- DUBs (1)
- Data mining (1)
- Data processing (1)
- Data science (1)
- David technique (1)
- Decision (1)
- Decision impact (1)
- Decision trees (1)
- Delayed union (1)
- Deletion mutation (1)
- Dental education (1)
- Dental students (1)
- Deutsches Rotes Kreuz (1)
- Diagnosis (1)
- Diagnostic markers (1)
- Diagnostic test (1)
- Direct Acting Antivirals (DAA) (1)
- Direct acting antiviral therapies (1)
- Disabling back pain (1)
- Disease burden (1)
- Distance to water (1)
- Docetaxel (1)
- Dog (1)
- Dopamine (1)
- Dorsolateral prefrontal cortex (1)
- Doxorubicin (1)
- Dual energy CT (1)
- Duodenal atresia (1)
- Duodenal stenosis (1)
- E protein structure (1)
- EEG (1)
- EGFP (1)
- EGFR inhibitor (1)
- ENCODE-DREAM in vivo Transcription Factor binding site prediction challenge (1)
- EPA (1)
- ERK3/MAPK6 (1)
- ERM (1)
- ERP (1)
- Economic analysis (1)
- Economics (1)
- Edentulous jaw (1)
- Education (1)
- Eicosanoids (1)
- Einreibetechnik (1)
- Einstellungen zu Impfungen (1)
- Electrical accident (1)
- Electrical stimulation (1)
- Electroencephalography – EEG (1)
- Electrolytes (1)
- Electrophysiology (1)
- Elektrischer Sturm (1)
- Elektrophysilogie (1)
- Elevation (1)
- Emergency (1)
- Emotion processing (1)
- Emotion regulation (1)
- Emotions (1)
- Empfehlungen (1)
- Employment (1)
- EndMT (1)
- Endoscopy (1)
- Endourologie (1)
- Ensemble learning (1)
- Enterobacteriaceae (1)
- Entfernung (1)
- Enzyme regulation (1)
- Enzyme-linked immunoassays (1)
- Epilepsy (1)
- Erythropoiesis (1)
- Esophageal adenocarcinoma (1)
- Esophageal adenocarcinoma (EAC) (1)
- Esophagectomy (1)
- Estrogen Receptor Modulators (1)
- Eukaryotic sRNA (1)
- Europe (1)
- European Society for Immunodeficiencies (ESID) (1)
- Evaluation (1)
- Evaluationspraxis (1)
- Evidence based medicine (1)
- Exercise challenge at an ambient temperature (1)
- Exercise challenge in a cold chamber (1)
- Exercise-induced bronchoconstriction (1)
- Experimental models of disease (1)
- Extended Glasgow outcome scale (eGOS) (1)
- Extracellular matrix proteins (1)
- Extracellular signal-regulated kinase 1/2 (1)
- Eyes (1)
- FAK (1)
- FFLU (1)
- FFPE (1)
- FIB-4 (1)
- Fatty acids (1)
- FemNAT-CD (1)
- Female adolescents (1)
- Femoral neck (1)
- Fettleber (1)
- Fevers (1)
- FibroMax (1)
- Fibroblast growth factor (1)
- Fibronectin (1)
- Fibrosis (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Finite Volumes (1)
- First site of metastatic disease (1)
- Fistula (1)
- Flaps (1)
- Fluorescence-in-situ-hybridization (FISH) (1)
- Foramen ovale (1)
- Forkhead box (1)
- Fracture risk (1)
- Francisella tularensis (1)
- Francisella tularensis subspecies holarctica (1)
- Frühgeburt (1)
- Functional electrical stimulation (1)
- Functional magnetic resonance imaging (1)
- Functional outcome (1)
- Funding (1)
- FungiScope® registry (1)
- G-protein (1)
- G/P (1)
- GRK2 (1)
- Gait analysis (1)
- Galleria mellonella (1)
- Gastric cancer (1)
- Gastroesophageal reflux disease (1)
- Gastroesophageal reflux disease symptoms (1)
- Gaucher disease type III (1)
- Gaucher’s disease (1)
- Gender reassigning surgery (1)
- Gene prediction (1)
- Gene regulation (1)
- General practice (1)
- General practitioner (1)
- General practitioners (1)
- Generation Y (1)
- Genome annotation (1)
- Genomic instability (1)
- Geographically weighted regression (GWR) (1)
- German PID-NET registry (1)
- German people (1)
- Gleason upgrading (1)
- Glioblastom (1)
- Glioblastoma (1)
- Global health (1)
- Glomerular Filtration Rate (1)
- Glucose Transporter Type 1 (1)
- Glycogen synthase kinase 3 beta (1)
- Goserelin (1)
- Grafts (1)
- Gram-negative bacteria (1)
- Grass pollen (1)
- Growth factors (1)
- Guided surgery (1)
- HAEGARDA (1)
- HAI‐1 (1)
- HCV (1)
- HDAC inhibition (1)
- HDACi (1)
- HER2/neu (ERBB2) (1)
- HGF (1)
- HIF1α (1)
- HIV (1)
- HNSCC (1)
- HOD (1)
- HODE (1)
- HPV (1)
- HSV-1 (1)
- HSV-2 (1)
- HUVEC (1)
- Haplotypes (1)
- Head and neck Cancer (1)
- Health care (1)
- Health economics (1)
- Health services research [MeSH] (1)
- Healthcare worker (1)
- Hedgehog (1)
- Hemoglobin (1)
- Hemophilia A (1)
- Hemorrhagic shock (1)
- HepG2 (1)
- HepaRG cells (1)
- Hepatitis B infection (1)
- Hepatitis B vaccination (1)
- Hepatocytes (1)
- Herafill (1)
- Hereditary angioedema (1)
- High-risk patient (1)
- Hippo signaling (1)
- Hippocampus (1)
- Histology (1)
- Hodgkin lymphoma (1)
- Holmes tremor (1)
- Homeostasis (1)
- Homicide (1)
- Hospitalizations (1)
- Host-directed therapies (1)
- HuR (1)
- Huh7 (1)
- Human (1)
- Human Immunodeficiency Virus (1)
- Human genetics (1)
- Human olfaction (1)
- Humeral fractures (1)
- Humerus (1)
- Hungary (1)
- Hydrocephalus (1)
- Hyperammonemic encephalopathy (1)
- Hypofractionated radiotherapy (1)
- Hypoxic responses (1)
- I-FABP (1)
- ICU (1)
- IGF (1)
- IL-15 (1)
- IL-1β (1)
- IL-21 (1)
- IL-27 cytokine (1)
- IL-33 (1)
- IL10R (1)
- ILUVIEN (1)
- IPEX (1)
- IPS e.max system (1)
- ISS (1)
- IUIS classification 2017 (1)
- IgE (1)
- IgG substitution therapy (1)
- IgGAM (1)
- Illumina (1)
- Image analysis (1)
- Imaging genetics (1)
- Immediate loading (1)
- Immediate placement (1)
- Immune Response (1)
- Immune cells (1)
- Immunoassays (1)
- Immunogenicity (1)
- Immunohistochemistry (1)
- Immunohistochemistry techniques (1)
- Immunomonitoring (1)
- Immunostaining (1)
- Immunosuppressive Agents (1)
- Impfkurs (1)
- Impfquoten (1)
- Implant-supported bars (1)
- In-line filtration (1)
- IncL (1)
- Incidence rate (1)
- Independent laboratories (1)
- Indirect-binding (1)
- Individual differences (1)
- Infarction (1)
- Infusion management (1)
- Insulin resistance (1)
- Integrated multimodal training (1)
- Intelligence (1)
- Intelligence tests (1)
- Intensive care (1)
- Intensive care units (1)
- Interleukin-17A (1)
- Interleukin-18 (1)
- Interleukin-18 binding protein (1)
- Interleukin-22 (1)
- Interleukin-22 binding protein (1)
- Interventional Trials (1)
- Interventional cardiology (1)
- Intracranial embolism (1)
- Intraoral scanners (1)
- Invasive fungal infection (1)
- Invasive fungal infections (1)
- Ipilimumab (1)
- Ireland (1)
- Iron deficiency (1)
- Iron deficiency anemia (1)
- JAK inhibition (1)
- Joint loading (1)
- KIF (1)
- KIF11 (1)
- Karyotypes (1)
- Katheterablation (1)
- Ketogenic Diet (1)
- Knochendefektheilung (1)
- Kolonkarzinom (1)
- L-DOPA (1)
- LAMTOR2 (1)
- LC-NE system (1)
- LC3 I/II (1)
- LC–MS/MS (1)
- LDL (1)
- LM11A 31 (1)
- LN229 (1)
- LPP (1)
- LRBA (1)
- LSCC (1)
- LSD1 (1)
- LUT (1)
- Labor and delivery (1)
- Laboratory techniques and procedures (1)
- Lafora disease (1)
- Laminin (1)
- Laparoscopic fundoplication (1)
- Late Gadolinium Enhancement (LGE) (1)
- Late presentation (1)
- Left hemisphere (1)
- Leg alignment (1)
- Legs (1)
- Leistungsorientierte Mittelvergabe (1)
- Lesion (1)
- Lesions (1)
- Liver (1)
- Liver Transplantation (1)
- Liver cancer (1)
- Liver fibrosis (1)
- Liver-Related Complications (1)
- Livestock (1)
- Local climate (1)
- Lomentospora prolificans (1)
- Long noncoding RNA (1)
- Long term output (1)
- Long-term (1)
- Luciferase (1)
- Lumbar spine (1)
- Lyme disease (1)
- Lymph nodes (1)
- Lymphadenopathy (1)
- Lymphangioleiomyomatosis (1)
- Lymphocytes (1)
- Lymphoid tissues (1)
- Lymphomas (1)
- Lysosomal storage disease (1)
- MAIT cell (1)
- MALAT1 (1)
- MEG (1)
- MMP2 (1)
- MRI patterns of gliomas (1)
- MRSA (1)
- Machine-learning (1)
- Magnetic resonance imaging (MRI) (1)
- Malaria (1)
- MammaPrint (1)
- Mammaplasty (1)
- Markov model (1)
- Masquelet (1)
- Masquelet technique (1)
- Mass spectrometry (1)
- Mastectomy (1)
- Maxillary sinus (1)
- Mechanisms of disease (1)
- Meckel’s diverticulum (1)
- Medical education (1)
- Medical research (1)
- Medicine and health sciences (1)
- Medizinische Ausbildung (1)
- Medizinstudierende (1)
- Membrane potential (1)
- Mesenchymal stem cell (1)
- Mesenchymal stromal cells (1)
- Metabolic syndrome (1)
- Metabolism (1)
- Metabolism, Inborn Errors (1)
- Metalloproteases (1)
- Metastasis (1)
- Metastatic castration-resistant prostate cancer (1)
- Metastatic tumors (1)
- Methacholine challenge test (1)
- Methicillin-resistant Staphylococcus aureus (1)
- MiSpEx Network (1)
- MicroRNAs (1)
- Microbiome (1)
- Microphones (1)
- Molecular profiling (1)
- Molecular signatures (1)
- Molecular subtype (1)
- Molecular subtypes (1)
- Monosaccharide Transport Proteins (1)
- Monte Carlo simulation (1)
- Morbidity (1)
- Morphogenesis (1)
- Motor control (1)
- Mouse models (1)
- Mucopolysaccharidoses (1)
- Multi-nucleated cardiomyocytes (1)
- Multidrug-resistant tuberculosis (1)
- Multinomial logistic regression (1)
- Multiresistente Erreger (1)
- NASH (1)
- NCH93 (1)
- NDR1 (1)
- NDUFAF8 (1)
- NEAT1 (1)
- NEAT2 (1)
- NGS (1)
- NK cell (1)
- NK cells (1)
- NK-92 (1)
- NKG2D (1)
- NKT cell (1)
- NMDA IgA/IgM antibodies (1)
- NMDA antibody (1)
- NMDAR subunit GluN2B (1)
- NOTCH1 (1)
- NPSR1 (1)
- NS3/4A-Protease (1)
- NSAIDs (1)
- Nanopore (1)
- Native T1 (1)
- Native T1 mapping (1)
- Nav channel activity (1)
- Nav1.7 (1)
- Neonatal urea cycle disorders (1)
- Neonates (1)
- Network model (1)
- Neuro-ophthalmology (1)
- Neuroblastom (1)
- Neuroimaging (1)
- Neuroscience (1)
- Nivolumab (1)
- Non-REM sleep (1)
- Non-coding RNA (1)
- Non-invasive brain stimulation (1)
- Non-small cell lung cancer (1)
- Nonunion (1)
- Notch (1)
- Nox4 (1)
- Numerical simulation (1)
- OXA-48 (1)
- Occupational medicine (1)
- Olfactory diagnostics (1)
- One health (1)
- Opacity (1)
- Oposterior urethral valve (1)
- Opportunistic infections (1)
- Optical lenses (1)
- Oral Health Impact Profile (OHIP) (1)
- Oral and maxillofacial surgery (1)
- Oral anticoagulation (1)
- Oral implantology (1)
- Oral surgery (1)
- Ordinary least squares (OLS) (1)
- Organ dysfunction (1)
- Oroantral (1)
- Oroantral communication (1)
- Osteogenic differentiation (1)
- Osteoporosis diagnosis (1)
- PCP (1)
- PCSK9 protein (1)
- PEI (1)
- PF-06273340 (1)
- PGE2 (1)
- PID prevalence (1)
- PINK1 (1)
- PKCδ (1)
- PKCε (1)
- PLK1 inhibitors (1)
- PPARγ (1)
- Paediatric research (1)
- Pain (1)
- Pancreatic surgery (1)
- Pancreatoduodenectomy (1)
- Panic disorder (1)
- Parapneumonic pleural effusion (1)
- Parkinson disease (1)
- Parkinson’s disease (1)
- Particles (1)
- Pathogenesis (1)
- Pathogenicity (1)
- Patient preferences (1)
- Pause (1)
- Pediatric patients (1)
- Pediatrics (1)
- Pentaglobin (1)
- Peritonitis (1)
- Personalised medicine (1)
- Pharm-fMRI (1)
- Pharmacometrics (1)
- Philadelphia chromosome-positive acute leukemia (1)
- Phylogenetic analysis (1)
- Physical environment (1)
- Platelet-rich fibrin (1)
- Platelets (1)
- Platzierung (1)
- Plerixafor (1)
- Pleural empyema (1)
- Pneumocystis jirovecii (1)
- Pneumonia (1)
- Polyunsaturated fatty acids (1)
- Ponatinib (1)
- Portal veins (1)
- Portugal (1)
- Posaconazole serum level (1)
- Positron-emission tomography (1)
- Post treatment (1)
- Precision (1)
- Precision oncology (1)
- Prenatal ultrasonographic detection rate (1)
- Preoperative diagnostics (1)
- Prevalence (1)
- Prevention (1)
- Primary care (1)
- Primary cilium (1)
- Primary health care [MeSH] (1)
- Prisoners (1)
- Prisons (1)
- Profilometry (1)
- Prognostic biomarker (1)
- Prognostische Marker (1)
- Prophylaxis (1)
- Prostaglandin (1)
- Prostate cancer (1)
- Prostate-specific membrane antigen (1)
- Prostatic neoplasms (1)
- Protease inhibitor therapy (1)
- Protein translation (1)
- Proteomics (1)
- Proteostasis (1)
- Proton density (1)
- Psychometric evaluation (1)
- Psychometrics (1)
- Q80K (1)
- Quality of care (1)
- Quantitative MRI (1)
- Questionnaires (1)
- REMS (1)
- RNA binding proteins (1)
- RNA extraction (1)
- RNA isolation (1)
- RNA-Bindeprotein (1)
- RNAi (1)
- RTS (1)
- RUCAM (1)
- Radiofrequenzablation (1)
- Radiotherapy (1)
- Rainfall (1)
- Rare Diseases (1)
- Re-injury (1)
- Reaction time (1)
- Reactive oxygen species (1)
- Real-world evidence (1)
- Recurrence (1)
- Red blood cell transfusion (1)
- Refractory ALL (1)
- Regenerative medicine (1)
- Regression analysis (1)
- Regulatory T cells (1)
- Rehabilitation (1)
- Relapsed ALL (1)
- Relaxometry (1)
- Renal system (1)
- Reproducibility (1)
- Research trends (1)
- Retina (1)
- Retro-IDEAL (1)
- Return to play (1)
- Return to sports (1)
- Rhabdomyosarcoma (1)
- Rheumatoid arthritis (1)
- Rheumatology (1)
- Rho/Rho-kinase (1)
- Rhythmologie (1)
- Ribosomes (1)
- Risk assessment (1)
- Risk prediction (1)
- Roe deer (1)
- Roughness (1)
- Roussel Uclaf Causality Assessment Method (1)
- Roussel Uclaf Causality Assessment Method (RUCAM) (1)
- Rural area (1)
- S1P (1)
- S1PR1 (1)
- SCA34 (1)
- SCA38 (1)
- SENP (1)
- SFR (1)
- SHH (1)
- SILAC (1)
- ST2L (1)
- STAT3 (1)
- SUMO (1)
- SUMO1-3 (1)
- SUMOylation (1)
- SUV (1)
- SW480 cells (1)
- SWATH (1)
- Saccades (1)
- Saccadometry (1)
- Safety (1)
- Salivary gland diseases (1)
- Salvage therapy (1)
- Sarcopenia (1)
- Scanner models (1)
- Scedosporium spp. (1)
- Schilddrüsenknoten (1)
- Screening (1)
- Screening guidelines (1)
- Secondary prevention (1)
- Seizure (1)
- Sensory perception (1)
- Sensory systems (1)
- Sequence motif analysis (1)
- Serine proteases (1)
- Serotype 3 (1)
- Severe bacterial infection (1)
- Sex differences (1)
- Signal transduction (1)
- Single-cell RNA-sequencing (1)
- Small RNA analysis (1)
- Smooth muscle cells (1)
- Social participation (1)
- Somatization (1)
- Specimen preparation and treatment (1)
- Speech signal processing (1)
- Spinalkanalstenose (1)
- Splanchnic Hemodynamics (1)
- Spontan bakterielle Peritonitis (1)
- Stammzelltransplantation (1)
- Staphylococcus aureus (1)
- Steatosis (1)
- Steinfreiheit (1)
- Stem cell (1)
- Stem cells (1)
- Stenosis (1)
- Sterblichkeit (1)
- Steroid (1)
- Streptococcus pneumoniae (1)
- Stress (1)
- Stress and resilience (1)
- Striatum (1)
- Stromal cell (1)
- Structured reporting (1)
- Subarachnoid hemorrhage (1)
- Subcutaneous (1)
- Sulforaphane (1)
- Sumatra (1)
- Surface (1)
- Surgical education (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic reviews (1)
- Systemic lupus erythematosus (1)
- Systems biology (1)
- Systems medicine (1)
- T cell (1)
- T cell receptors (1)
- TBK1 (1)
- TCR signaling cascade (1)
- TEER (1)
- TF-complexes (1)
- TGF-β1 (1)
- TILs (1)
- TIMP2 (1)
- TKI (1)
- TMEM126B (1)
- TMS (1)
- TMT (1)
- TP53-induced glycolysis and apoptosis regulator (1)
- TRIM25 (1)
- Tacrolimus (1)
- Target identification (1)
- Targeted therapies (1)
- Taxane (1)
- Tea (1)
- Telomere length (1)
- Telomeres (1)
- Texture analysis (1)
- Theft (1)
- Therapy (1)
- Therapy response (1)
- Thoracic trauma (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombotic microangiopathy (1)
- Thrombotic thrombocytopenic purpura (1)
- Thromboxane (1)
- Thymocytes (1)
- Thymus (1)
- Tick (1)
- Time in therapeutic range (TTR) (1)
- Time to treatment failure (1)
- Tissue microarray (TMA) (1)
- Toll-like Rezeptor, Subcommissuralorgan; Circumventriculäre Organe (1)
- Tools and ressources (1)
- Total hip replacement (1)
- Toxicity (1)
- Transcription Factors (1)
- Transcriptional control (1)
- Transfusionsbedingte virale Infektionen (1)
- Transgender (1)
- Transiente Elastographie (1)
- Translation initiation (1)
- Translational (1)
- Translational research (1)
- Trees (1)
- Treg cell (1)
- Trimeric autotransporter adhesins (1)
- Trk (1)
- TrkC (1)
- Trousseau’s syndrome (1)
- Trueness (1)
- Tularemia (1)
- Tumor heterogeneity (1)
- Tumour immunology (1)
- U-87MG (1)
- URS (1)
- Ulcerative colitis (1)
- Ultrasonography (1)
- Ultrasound (1)
- Umbilical cord (1)
- Unilateral hip osteoarthritis (1)
- United States (1)
- Ureterorenoskopie (1)
- Uveal melanoma (1)
- VARGADO (1)
- VDR (1)
- VEGFA (1)
- VGAT-ChR2 (1)
- VISTA (1)
- VT (1)
- Vaccination (1)
- Vaccine breakthrough (1)
- Vacuoles (1)
- Validation (1)
- Vascular disease (1)
- Vasculogenesis (1)
- Veins (1)
- Video-oculography (1)
- Viral load (1)
- Virtual implant planning (1)
- Virtual patients (1)
- Virulence (1)
- Visual acuity (1)
- Visual impairments (1)
- Visual system (1)
- Vitamin K antagonists (1)
- Vitreous opacity (1)
- Vmem (1)
- Volume overload (1)
- Voriconazole (1)
- WNT (1)
- WT1 (1)
- Westphal-Paradigm (1)
- White blood cells (1)
- WoMo score (1)
- Working memory (1)
- Wound healing (1)
- Zebrafish (1)
- Zika virus (1)
- Zoonosis (1)
- Zoopotentation (1)
- Zooprophylaxis (1)
- abuse (1)
- accidents (1)
- acid sphingomyelinase (ASMase; Smpd1) (1)
- acneiform skin toxicity (1)
- acoustic radiation force impulse imaging (1)
- acute decompensation (1)
- acute liver failure (1)
- acute lung injury (1)
- acute lung injury (ALI) (1)
- acute-on-chronic liver failure (1)
- adalimumab (1)
- adeno-associated virus (1)
- adeno‐associated virus (1)
- adherence (1)
- adhesion (1)
- adipocytes (1)
- adiponectin (1)
- adipose tissue (1)
- adipose-derived mesenchymal stem cells (1)
- adipose-derived stem cells (1)
- adolescents (1)
- adoptive cancer immunotherapy (1)
- adrenal insuffciency (1)
- adult attention deficit/hyperactivity disorder (adult ADHD) (1)
- adverse effects (1)
- ageing (1)
- aging (1)
- air flow (1)
- air pollution (1)
- airborne bacteria (1)
- albumin (1)
- alcohol (1)
- alcohol dehydrogenase (ADH) (1)
- alcohol metabolism (1)
- alcoholic liver disease (1)
- alcoholic liver injury (1)
- alloHSCT (1)
- allogeneic stem cell transplantation (1)
- alpha receptor (1)
- alpha-synuclein (1)
- amisulpride (1)
- amyotrophic lateral sclerosis (ALS) (1)
- anaemia (1)
- anal cancer (1)
- anaplastic large cell lymphoma (1)
- angio-immunogenic switch (1)
- animal models (1)
- anti-cancer therapy (1)
- antibodies (1)
- anticonvulsant (1)
- antiepileptic drug (1)
- antifibrotic therapy (1)
- antifungal therapy (1)
- antisynthetase antibodies (1)
- antisynthetase syndrome (1)
- antiviral drugs (1)
- apigenin (1)
- aromatics (1)
- arthritis (1)
- artificial intelligence (1)
- ascites (1)
- associative memory (1)
- astrocytoma (1)
- ataxia score (1)
- ataxia telangiectasia (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- attention modulation (1)
- attention-deficit/hyperactivity disorder (1)
- attention-deficit/hyperactivitydisorder (1)
- attractiveness (1)
- augmentation (1)
- authentication (1)
- autism spectrum disorder (1)
- autologous stem cell transplantation (1)
- automated patch-clamp (1)
- azaindole (1)
- bacteria (1)
- basic mechanisms (1)
- basonuclin 2 (1)
- beam quality correction factors (1)
- belimumab (1)
- beta‐trace protein (1)
- bevacizumab (1)
- binary search procedure (1)
- bioacoustics (1)
- bioactivity (1)
- biofilm (1)
- biological treatments (1)
- biologics (1)
- biomarkers (1)
- biopsy (1)
- bipolar disorder (1)
- bladder cancer (1)
- bladder dose (1)
- blood flow restriction (1)
- bmal1 (1)
- body mass index (1)
- bone chips (1)
- bone damage (1)
- bone healing (1)
- bone loss (1)
- bone marrow derived mononuclear cells (1)
- bone marrow mononuclear cells (1)
- bone morphogenetic proteins (BMPs) (1)
- bone regeneration (1)
- bone‐screw (1)
- bone–implant interface (1)
- borrelia (1)
- borrelia mayonii (1)
- brachytherapy (1)
- brain phosphorylome (1)
- brain states (1)
- bronchial allergen provocation (1)
- cadherin (1)
- calcitriol (1)
- callous-unemotional traits (1)
- calprotectin (1)
- calretinin (1)
- calretinin-knock out (1)
- cancer cell metabolism (1)
- cancer patients (1)
- cancer stem cells (1)
- cancer treatment (1)
- cancer-associated fibroblasts (1)
- cancer-specific survival (1)
- cannabis (1)
- cap-dependent translation (1)
- capsaicin (1)
- car indoor (1)
- carbapenemases (1)
- carbon oxides (COx) (1)
- cardiac myocytes (1)
- cardiomegaly (1)
- cardiovascular (1)
- cardiovascular management (1)
- case reports (1)
- caspase 8 (1)
- caspase-8 (1)
- catheter removal (1)
- cdk (1)
- cell adhesion (1)
- cell biology (1)
- cell cycle arrest (1)
- cell cycling (1)
- cell death (1)
- cell growth (1)
- cell line (1)
- cell motility (1)
- cell survival mechanisms (1)
- cell therapy (1)
- centrifugation (1)
- ceramide (1)
- ceramide synthase (CERS2/CERS1) (1)
- cerebral radiation necrosis (1)
- cerebrovascular disease (1)
- ceritinib (1)
- cervical cancer (1)
- channelrhodopsin (1)
- characterization (1)
- checkpoint proteins (1)
- chemokine receptors (1)
- chemoradiotherapy (1)
- chemoresistance (1)
- chemotherapy (1)
- chemotherapy resistance (1)
- chest injury (1)
- chest trauma (1)
- child (1)
- childhood abuse (1)
- children (1)
- chimeric antigen receptor (1)
- chronic myeloid leukemia (1)
- chronobiology (1)
- cigarette strength (1)
- cigarettes (1)
- circadian rhythm (1)
- circulating miRNA (1)
- classical conditioning (1)
- classification of bone defects (1)
- clinical immunology (1)
- clinical research (1)
- clinical study (1)
- clinical trial (1)
- cloacae (1)
- clock genes (1)
- clonal dominance (1)
- clonal hematopoiesis (1)
- cochlear implant (1)
- cognitive deficits (1)
- cognitive functions (1)
- collagen (1)
- collagen I (1)
- collagen degradation marker (1)
- collateral sprouting (1)
- colon carcinoma cells (1)
- colorectal carcinoma (1)
- combination treatment (1)
- common variant (1)
- complex I (1)
- complex I deficiency (1)
- compliance (1)
- computational models (1)
- computational neuroscience (1)
- computational techniques (1)
- computational virology (1)
- concordance (1)
- conduct disorder (1)
- connective tissue graft (1)
- consensus paper (1)
- convolution neural network (1)
- coordination (1)
- copeptin (1)
- cornea donor (1)
- coronary artery bypass graft surgery (1)
- cortical malformation (1)
- cortical thickness (1)
- cortisol (1)
- cost-effective (1)
- courting behavior (1)
- critical size defect (1)
- critically ill patients (1)
- cross-frequency coupling (1)
- cross-sectional study (1)
- cryopreservation (1)
- cyclin D1 (1)
- cyclins (1)
- cyclosporine (1)
- cystatin C (1)
- cystic fibrosis (1)
- cytochrome P450 2E1 (1)
- cytokine, angiogenesis (1)
- cytotoxic T cells (1)
- death (1)
- death receptor (1)
- deep neural network (1)
- defect configuration (1)
- delayed wound healing (1)
- dental implants (1)
- depressive symptoms (1)
- desmoplastic small round cell tumor (1)
- detoxification (1)
- diabetic neuropathy (1)
- diffusion tensor imaging (1)
- diffusion tensor imaging (DTI) (1)
- dimethylfumarate (1)
- direct-acting antivirals (DAAs) (1)
- directed disulfide bond formation (1)
- discoidin domain-containing receptor (1)
- discomfort/pain (1)
- disease-free survival (1)
- dissemination (1)
- distal pronephric outlet obstruction (1)
- distress (1)
- docetaxel (1)
- dopamine (1)
- dosimetry (1)
- double inversion recovery (DIR) (1)
- doxorubicin (1)
- drilling tool design (1)
- drug induced liver injury (1)
- drug metabolism and distribution (1)
- drug release (1)
- drug resistance (1)
- drug targets (1)
- drug therapy (1)
- drug-induced liver injury (1)
- drug-induced liver injury (DILI) (1)
- dual task (1)
- dynamic 18F-FDG PET/CT (1)
- early continence (1)
- early loss (1)
- early tumor stages (1)
- economy (1)
- edema (1)
- ejection fraction (EF) (1)
- elderly patients (1)
- electrical stimulation (1)
- electrocardiography (1)
- electron transport chain (1)
- electrophysiology (1)
- eltrombopag (1)
- emergency care (1)
- emergent self-organizing maps (1)
- emotional information processing (1)
- empowerment (1)
- endometriosis (1)
- endophytes (1)
- endoplasmic reticulum (1)
- endothelial cell (1)
- endothelial cells (1)
- endothelial to mesenchymal transition (1)
- endotoxins (1)
- entorhinal cortex lesion (1)
- envelope technique (1)
- eosinophil cationic protein (1)
- eosinophils (1)
- epigenetic (1)
- epigenetics (1)
- epigenome (1)
- euthymic (1)
- evaluation (1)
- evaluation practice (1)
- everolimus (1)
- evoked response (1)
- evolution (1)
- ex vivo expansion (1)
- excess fluid volume (1)
- executive function (1)
- exercise training (1)
- exosomes (1)
- expression studies (1)
- extracellular vesicles (1)
- eye tracking (1)
- face-name association task (1)
- factor H (1)
- factor IX (1)
- factor VIII (1)
- fat (1)
- fatty acid elongase (Elovl1/4/5) (1)
- fatty acids (1)
- feedback (1)
- femoral artery ligation (1)
- fibroblasts (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fidaxomicin (1)
- fitness (1)
- fixed partial dentures (1)
- fizička aktivnost; (1)
- flavivirus entry factor (1)
- flow cytometry (1)
- fluorescent dye (1)
- focal adhesion (1)
- focal cortical dysplasia (FCD) (1)
- fresh frozen plasma (1)
- full-contour crown restorations (1)
- functional connectivity (1)
- functional genetics (1)
- fungal pathogens (1)
- fungi (1)
- fusion (1)
- gRNA library (1)
- gadolinium‐based contrast agent (1)
- gel spacer injection (1)
- gender (1)
- gender dysphoria (1)
- gender-affirming hormone therapy (1)
- gene expression (1)
- gene expression analysis (1)
- gene regulation (1)
- gene signature (1)
- gene therapy (1)
- genetics (1)
- genetics and genomics (1)
- gene×environment interactions (1)
- genome-wide (1)
- glecaprevir (1)
- glial activation (1)
- glioblastoma (GBM) (1)
- global diversity (1)
- glutamate (1)
- glutamine (1)
- gossypol (1)
- graft-versus host (1)
- granulocytecolony stimulating factor (1)
- granuloma (1)
- gray‐white matter blurring (1)
- growth (1)
- growth hormone (1)
- growth inhibition (1)
- gut microbiota (1)
- haemophilia (1)
- head and neck cancer (1)
- head-to-head (1)
- health apps (1)
- health‐related quality of life (1)
- heart (1)
- heart rate (1)
- heat (1)
- hematopoiesis (1)
- hematopoietic stem cell mobilization (1)
- hematopoietic stem cells (1)
- hematopoietic stress (1)
- hepatic osteodystrophy (1)
- hepatic phenotype (1)
- hepatic steatosis (1)
- hepatitis B (1)
- hepatitis B virus (1)
- hepatitis C virus (HCV) (1)
- herb induced liver injury (1)
- hereditary angioedema (1)
- high molecular weight plasticizer (1)
- high-dimensional data sets (1)
- high-dose-rate interstitial brachytherapy (1)
- high-energy photon and proton radiation (1)
- histone deacetylases (HDACs) (1)
- hospital exemption (1)
- host cell interaction (1)
- host cell response (1)
- host immune response (1)
- host-directed therapies (1)
- hostpathogen interaction (1)
- human Natural Killer cell (1)
- human antigen R (HuR) (1)
- human biology and medicine (1)
- human cytomegalovirus (1)
- human immunodeficiency virus (1)
- human skin graft (1)
- humectant agents (1)
- hygienic hand disinfection (1)
- hygienische Händedesinfektion (1)
- hypertension and anti-hypertensive treatment (1)
- hypoparathyroidism (1)
- hypoxia-inducible factor (1)
- idiopathic dystonia (1)
- idiopathic pulmonary fibrosis (1)
- idiosyncratic DILI (1)
- ifenprodil (1)
- illness experiences (1)
- image analysis (1)
- immune deficiency (1)
- immune dysregulation (1)
- immune landscape (1)
- immune responses (1)
- immune system (1)
- immune-checkpoint inhibition (1)
- immunity (1)
- immunoglobulin superfamily (1)
- immunological research (1)
- immunology and infectious diseases (1)
- immunosuppressive agent (1)
- immunosuppressive drug (1)
- implant movement (1)
- implant stability (1)
- in silico simulation (1)
- in vivo micro‐CT (1)
- in-cabin exposure (1)
- indication (1)
- individual differences (1)
- indomethacin (1)
- induced membrane (1)
- infiltration (1)
- inflammatory bowel disease (1)
- information transfer (1)
- inhibitory interneurons (1)
- insect herbivory (1)
- insertion (1)
- insula (1)
- integrated stress response (1)
- intensive care unit (1)
- interferon gamma (1)
- internal ribosomal entry site (IRES) (1)
- interstitial lung disease (1)
- intestinal barrier (1)
- intrinsic DILI (1)
- intrinsic apoptosis (1)
- invasive fungal disease (1)
- ionotropic glutamate receptors (1)
- iron chelation (1)
- iron chelator (1)
- iron chelators (1)
- iron deficiency (1)
- iron homeostasis (1)
- iron metabolism (1)
- irradiation (1)
- isogenic (1)
- ixekizumab (1)
- junctional adhesion molecule (1)
- juvenile myoclonic epilepsy (1)
- kidney transplantation (1)
- kinesin (1)
- lapatinib (1)
- latent tuberculosis infection (1)
- left ventricular function (1)
- legal gender reassignment (1)
- leukocytes (1)
- leukodystrophy (1)
- lifelong learning (1)
- light transmission aggregometry (1)
- liminality (1)
- linoleic acid metabolites (1)
- lipid mediator (1)
- lipid metabolism (1)
- lipids (1)
- lipids inflammatory pain (1)
- lipocalin-2 (1)
- lipopolyplex (1)
- lipopolysaccharide (1)
- lipoxygenase (1)
- liquid-PRF (1)
- liver (1)
- liver adaption (1)
- liver cancer (1)
- liver cell lines (1)
- liver diseases (1)
- liver fibrosis (1)
- liver injury (1)
- liver metabolism (1)
- local control (1)
- long-term distress (1)
- longitudinal relaxation time T1 (1)
- low speed centrifugation concept (1)
- low-back pain (1)
- low-cost medication (1)
- lower urinary tract obstruction (1)
- luteolin (1)
- lyme disease (1)
- lymphangiogenesis (1)
- mGluR3 (1)
- mGluR5 (1)
- mRNA active cancer immunotherapy (1)
- mRNA decay (1)
- mRNA stability (1)
- mTOR inhibition (1)
- mTORC1 (1)
- machine learning (1)
- machine-learning (1)
- maintenance therapy (1)
- major adverse cardiac events (1)
- major depressive disorder (1)
- malignant glioma (1)
- mammary cancer (1)
- mammary carcinoma (1)
- marathon (1)
- maraton (1)
- mass spectrometry (1)
- massive weight loss (1)
- massively parallel multigrid solvers (1)
- mathematical models of viral RNA cycle (1)
- matrix metalloproteinase (1)
- mechanistic target of rapamycin (mTOR) (1)
- medial thigh lift (1)
- medical error (1)
- medulloblastoma resection (1)
- memantine (1)
- memory (1)
- meningioma (1)
- merkel cell carcinoma (1)
- mesenchymal stromal cell (1)
- mesenchymal stromal/stem cells (1)
- metabolites (1)
- metastasis (1)
- metastates (1)
- metformin (1)
- methylation profiling (1)
- miR (1)
- miR-143-3p (1)
- miR-181 (1)
- miR-375 (1)
- mice (1)
- microbiome (1)
- microdosing (1)
- microglia (1)
- microsomal ethanol-oxidizing system (MEOS) (1)
- microtubular cytoskeleton (1)
- microtubule disruptors (1)
- mild cognitive impairment (1)
- mitochondrial bioenergetics and glycolysis (1)
- mitochondrial disease (1)
- mitophagy (1)
- mobile air quality study (1)
- mobile phone apps (1)
- mobile tongue cancer (1)
- modeling (1)
- molecular diagnosis (1)
- molecular marker (1)
- montelukast (1)
- motility (1)
- mouse (1)
- mouse model (1)
- movement disorders (1)
- mpMRI (1)
- mtor (1)
- mucosal inflammation (1)
- mucositis (1)
- multidisciplinary pain treatment (1)
- multimorbidity (1)
- multiplex immunofluorescence (1)
- musician (1)
- mutations (1)
- mycophenolate mofetil [MMF] (1)
- myeloid cells (1)
- myocardial infarction (1)
- myocardial injury (1)
- myocardium (1)
- myogenic tone (1)
- myogenic vasoconstriction (1)
- myositis (1)
- nadp (1)
- nanoparticles (1)
- natural killer cells (1)
- nematophin (1)
- neoplasms (1)
- nerve-sparing (1)
- network analysis (1)
- network neuroscience (1)
- neural network (1)
- neuroblastoma (1)
- neurodegeneration (1)
- neurodevelopmental disorders (1)
- neuronal silencing (1)
- neurons (1)
- neuropathic pain (1)
- neuropsychological impairment (1)
- neurotrophins (1)
- neutral ceramidase (Asah2) (1)
- neutral sphingomyelinase (Smpd3) (1)
- new miRNA functions (1)
- nintedanib (1)
- nitrogen oxides (NOx) (1)
- nocardia (1)
- nocardiosis (1)
- nodular sclerosis (1)
- non-classical adhesion molecule (1)
- non-invasive fibrosis assessment (1)
- non-sensory bias (1)
- non-small-cell lung cancer (1)
- noradrenaline (1)
- norepinephrine (1)
- nutrient deprivation (1)
- observational cohort study (1)
- oksidacioni stres (1)
- older patients (1)
- olivo-ponto-cerebellar atrophy (OPCA) (1)
- oncogene (1)
- oncolytic virotherapy (1)
- optogenetics (1)
- organ dysfunction (1)
- organ failure (1)
- organisation of health services (1)
- organophosphate flame retardants (OFR) (1)
- orthodontic mini‐implant (1)
- oscillator (1)
- osteoarthritis (1)
- osteogenesis (1)
- osteopenia (1)
- osteotomy (1)
- outcome (1)
- overall survival (1)
- overweight (1)
- oxidative stress (1)
- p14 (1)
- p62 (1)
- p75 (1)
- pack-years (PY) (1)
- pain (1)
- pain management (1)
- pain target (1)
- palatal tremor (1)
- particle size distribution (1)
- particulate matter (PM) (1)
- passive reading paradigm (1)
- patent (1)
- patient (1)
- patient and public involvement (1)
- patient blood management (1)
- patient perspective (1)
- patient preference (1)
- patient safety (1)
- patients' experience (1)
- patient‐centred outcomes (1)
- pazopanib (1)
- pediatric patients (1)
- pedicle screws (1)
- peficitinib (1)
- perforant path transection (1)
- performance evaluation (1)
- performance-based funding allocation (1)
- perinatal (1)
- perio-prosthetic joint infection (1)
- periodontal probing, (1)
- periodontitis (1)
- peripartal (1)
- perirenal (1)
- peri‐implant lesions (1)
- peri‐implant probing (1)
- peri‐implantitis (1)
- pharmaco-fMRI (1)
- pharmacodynamics (1)
- pharmacogenetics (1)
- pharmacoresistance (1)
- phase 3 study (1)
- phosphatases (1)
- phylogenetic analysis (1)
- physical activity (1)
- pibrentasvir (1)
- pitch perception (1)
- placement (1)
- plant growth (1)
- plant resistance (1)
- plant-insect interactions (1)
- plasmid (1)
- plastic (1)
- plasticity (1)
- platelet aggregation (1)
- platelet lysate (1)
- platelet rich plasma (1)
- platelet-rich fibrin (1)
- platelets (1)
- platform switching (1)
- pleuropericarditis (1)
- point shear wave elastography (1)
- polo-like kinase 1 (1)
- polo-like kinase 3 (1)
- poly(lactic-co-glycolic acid) (PLGA) (1)
- polyethylenimine (1)
- polyomavirus (MCPyV) (1)
- polypharmacology (1)
- population dynamics (1)
- post-translational modifications (PTMs) (1)
- posterior fossa masses (1)
- postmortem blood samples (1)
- posttraumatic stress disorder (1)
- post‐traumatic stress disorder (1)
- power dynamics (1)
- pranlukast (1)
- pre-clinical models (1)
- preeclampsia (1)
- prefrontal cortex (1)
- preoperative anaemia management (1)
- pressure cycling technology (1)
- pressure ulcer treatment (1)
- preterm birth (1)
- primary cilium (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- progestin (1)
- prognosis (1)
- progressive myoclonus epilepsy (1)
- pronephric development (1)
- prophylaxis (1)
- prospective studies (1)
- protein tagging (1)
- proto-oncogene proteins c-akt (1)
- proton density (1)
- proton pump inhibitors (1)
- psoriatic arthritis (1)
- psychological distress (1)
- psychophysiology (1)
- psychosocial stress (1)
- public health (1)
- pulmonary nocardiosis (1)
- pulse labeling (1)
- pulse-spreading harmonic complex (1)
- pupil dilation (1)
- pupillary reactivity (1)
- qualitative research (1)
- quality assurance (1)
- quantitative T1 mapping (1)
- quantitative T1‐difference maps (1)
- radiation therapy (1)
- radioimmunotherpay (1)
- radioresponse (1)
- radixin (1)
- randomized (1)
- rare variant (1)
- re-emerging virus (1)
- re-osseointegration (1)
- reactivation (1)
- reactive oxygen species (ROS) (1)
- reaktivne vrste kiseonika (1)
- real-world data (1)
- realistic geometries (1)
- recertification (1)
- recommendations (1)
- recurrent laryngeal nerve palsy (1)
- refractory aGvHD (1)
- regeneration (1)
- registry for primary immunodeficiency (1)
- regorafenib (1)
- regorafenib csf concentration (1)
- relaxometry (1)
- remote monitoring (1)
- removal (1)
- renal cell cancer (1)
- renin-angiotensin system (1)
- reorganization (1)
- repeat DMEK (1)
- reservoir computing (1)
- resistance (1)
- resistance-associated substitutions (RAS) (1)
- resting-state fMRI (1)
- resting‐state (1)
- retrospective (1)
- revalidation (1)
- revision surgery (1)
- rhabdomyosarcoma (1)
- rhabdomyosarcomas (1)
- rheumatoid arthritis (1)
- ribavirin (1)
- right ventricular function (1)
- risk factor progression (1)
- risk genes (1)
- risk management (1)
- root coverage (1)
- rosetting T cells (1)
- rub-in technique (1)
- running wheel (1)
- sRNA (1)
- sRNA tool (1)
- safety (1)
- scaffold size (1)
- schizophrenia (1)
- schizophrenia spectrum (1)
- schwangerschaftsdepression (1)
- sclerostin (1)
- scoping review (1)
- screening test (1)
- screw augmentation (1)
- screw loosening (1)
- second-hand smoke (1)
- secretion (1)
- seed germination (1)
- segmentation (1)
- seizure (1)
- selectin (1)
- sensorimotor exercise training (1)
- sensory neuropathy (1)
- sensory processing (1)
- serine palmitoyltransferase 2 (Sptlc2) (1)
- serologic screening (1)
- serositis (1)
- serum albumin deficiency (1)
- severe vitamin D deficiency (1)
- sex differences (1)
- sexually transmitted diseases (1)
- sexually transmitted infection (1)
- sham (1)
- shortening of treatment (1)
- shunt (1)
- siRNA analysis (1)
- siRNA delivery (1)
- siRNA quantification (1)
- siRNA/RNAi (1)
- signature (1)
- silicone device (1)
- simulation (1)
- simulation training (1)
- single-sided deafness (1)
- sinus rhythm (1)
- six-step technique (1)
- sleep (1)
- smoking (1)
- sofosbuvir (1)
- soft tissue sarcoma (1)
- soft tissue sarcoma (STS) (1)
- soluble epoxide hydrolase (1)
- somatic mutations (1)
- sonic hedgehog signaling (1)
- sound-induced flash illusion (1)
- spatial specificity (1)
- spectroscopy (1)
- sphingolipid (1)
- spider toxin (1)
- spiking neural networks (1)
- spinal fusion (1)
- spirochete (1)
- spirochetes (1)
- starvation (1)
- stem cell transplantation (1)
- steroid-resistant aGvHD (1)
- stimulation (1)
- stopping rule (1)
- stratification (1)
- strength training (1)
- stress response (1)
- stroke (1)
- structural covariance (1)
- subcutaneous fat (1)
- subjunctivity (1)
- success rate (1)
- sulfasalazine (1)
- suplementacija (1)
- supplementation (1)
- support vector machines (1)
- surveillance (1)
- survival (1)
- survival rate (1)
- synaptic signaling (1)
- synovial fibroblast (1)
- systemic inflammation (1)
- t-distributed stochastic neighbor embedding (1)
- tDCS (1)
- tacrolimus (1)
- target variability (1)
- telemedicine (1)
- telmisartan (1)
- temozolomide (1)
- temsirolimus (1)
- temsirolimus-resistance (1)
- thighplasty (1)
- thrombocyte dysfunction (1)
- thrombocyte function (1)
- thrombolysis (tPA) (1)
- thrombopietin receptor agonist (1)
- thrombospondin-4 (1)
- thymus (1)
- thyroid resection (1)
- tissue Doppler imaging (1)
- tissue engineering (1)
- tolerance (1)
- tongue edema (1)
- topographic maps (1)
- total joint arthroplasty (TJA) (1)
- traffic emissions (1)
- trafficking (1)
- transcriptional profiling (1)
- transcriptome (1)
- transdifferentiation (1)
- transforming growth factor beta (1)
- transforming growth factor beta (TGF-β) (1)
- transient elastography (1)
- transient receptor potential channels (1)
- translation (1)
- transmission and vector control (1)
- transsexualism (1)
- trastuzumab (1)
- trophoblastic cell lines (1)
- trophoblasts (1)
- troponin (1)
- tumor (1)
- tumor growth (1)
- tumor immune evasion (1)
- tumor microenviroment (1)
- tumor progression (1)
- tumor proliferation (1)
- tumor‐associated macrophages (1)
- two-tissue compartment model (1)
- tyrosine kinase inhibitor (1)
- ulcerative colitis (1)
- uncertainty (1)
- unfolded protein response (1)
- ustekinumab (1)
- uterine cervical cancer (1)
- vaccine (1)
- valproic acid (1)
- vancomycin (1)
- vascular complications (1)
- vascular disease (1)
- vascular dysfunction and inflammation (1)
- vascular smooth muscle (1)
- velpatasvir (1)
- ventral tegmental area (1)
- vesicovaginal septum (1)
- viability (1)
- viral dynamics (1)
- viral gene transfer (1)
- virulence (1)
- vitamin D supplementation (1)
- vitamin D target genes (1)
- vitamin Dmetabolism (1)
- voice (1)
- volatile organic compounds (VOC) (1)
- voluntary training (1)
- voxilaprevir (1)
- within-host viral modeling (1)
- wochenbettdepression (1)
- women (1)
- words (1)
- work-life balance (1)
- working conditions (1)
- wound healing (1)
- yellow fever virus (1)
- yellow fever virus tropism (1)
- zafirlukast (1)
- zebrafish (1)
- zirconia (1)
- Überwachung (1)
- β-catenin (1)
- β-lactamases (1)
- γδT cell (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- flow cytometry (1)
Institute
- Medizin (576) (remove)
Prescribing practice of pregabalin/gabapentin in pain therapy : an evaluation of German claim data
(2019)
Objectives: To analyse the prevalence and incidence of pregabalin and gabapentin (P/G) prescriptions, typical therapeutic uses of P/G with special attention to pain-related diagnoses and discontinuation rates.
Design: Secondary data analysis.
Setting: Primary and secondary care in Germany.
Participants: Four million patients in the years 2009–2015 (anonymous health insurance data).
Intervention: None.
Primary and secondary outcome measures: P/G prescribing rates, P/G prescribing rates associated with pain therapy, analysis of pain-related diagnoses leading to new P/G prescriptions and the discontinuation rate of P/G.
Results: In 2015, 1.6% of insured persons received P/G prescriptions. Among the patients with pain first treated with P/G, as few as 25.7% were diagnosed with a typical neuropathic pain disorder. The remaining 74.3% had either not received a diagnosis of neuropathic pain or showed a neuropathic component that was pathophysiologically conceivable but did not support the prescription of P/G. High discontinuation rates were observed (85%). Among the patients who had discontinued the drug, 61.1% did not receive follow-up prescriptions within 2 years.
Conclusion: The results show that P/G is widely prescribed in cases of chronic pain irrespective of neuropathic pain diagnoses. The high discontinuation rate indicates a lack of therapeutic benefits and/or the occurrence of adverse effects.
Cysteinyl leukotriene receptor 1 antagonists (CysLT1RA) are frequently used as add-on medication for the treatment of asthma. Recently, these compounds have shown protective effects in cardiovascular diseases. This prompted us to investigate their influence on soluble epoxide hydrolase (sEH) and peroxisome proliferator activated receptor (PPAR) activities, two targets known to play an important role in CVD and the metabolic syndrome. Montelukast, pranlukast and zafirlukast inhibited human sEH with IC50 values of 1.9, 14.1, and 0.8 μM, respectively. In contrast, only montelukast and zafirlukast activated PPARγ in the reporter gene assay with EC50 values of 1.17 μM (21.9% max. activation) and 2.49 μM (148% max. activation), respectively. PPARα and δ were not affected by any of the compounds. The activation of PPARγ was further investigated in 3T3-L1 adipocytes. Analysis of lipid accumulation, mRNA and protein expression of target genes as well as PPARγ phosphorylation revealed that montelukast was not able to induce adipocyte differentiation. In contrast, zafirlukast triggered moderate lipid accumulation compared to rosiglitazone and upregulated PPARγ target genes. In addition, we found that montelukast and zafirlukast display antagonistic activities concerning recruitment of the PPARγ cofactor CBP upon ligand binding suggesting that both compounds act as PPARγ modulators. In addition, zafirlukast impaired the TNFα triggered phosphorylation of PPARγ2 on serine 273. Thus, zafirlukast is a novel dual sEH/PPARγ modulator representing an excellent starting point for the further development of this compound class.
Selection and prioritization of patients with HCC for LT are based on pretransplant imaging diagnostic, taking the risk of incorrect diagnosis. According to the German waitlist guidelines, imaging has to be reported to the allocation organization (Eurotransplant) and pathology reports have to be submitted thereafter. In order to assess current procedures we performed a retrospective multicenter analysis in all German transplant centers with focus on accuracy of imaging diagnostic and tumor classification. 1168 primary LT for HCC were conducted between 2007 and 2013 in Germany. Patients inside the Milan, UCSF, and up-to-seven criteria were misclassified with definitive histologic results in 18%, 15%, and 11%, respectively. Patients pretransplant outside the Milan, UCSF, and up-to-seven criteria were otherwise misclassified in 34%, 43%, and 41%. Recurrence-free survival correlated with classification by posttransplant histological report, but not pretransplant imaging diagnostic. Univariate analysis revealed tumor size, vascular invasion, and grading as significant parameters for outcome, while tumor grading was the only parameter persisting by multivariate testing. Conclusion. There was a relevant percentage (15-40%) of patients misclassified by imaging diagnosis at a time prior to LI-RADS and guidelines to improve imaging of HCC. Outcome analysis showed a good correlation to histological, in contrast poor correlation to imaging diagnosis, suggesting an adjustment of the LT selection and prioritization criteria.
Background: Hepatitis C virus (HCV) is currently classified into 8 genotypes and 86 subtypes. The objective of this study was to characterize novel HCV subtypes and to investigate the impact of subtypes on treatment outcome.
Methods: Full-genome sequencing was performed on HCV plasma samples with <85% sequence homology of NS3, NS5A, and/or NS5B to HCV genotype (GT) 1–8 reference strains.
Results: A total of 14 653 patients with GT1–6 HCV infection were enrolled in clinical studies of sofosbuvir-based regimens. For the majority of the patients, a specific subtype could be assigned based on a close genetic relationship to previously described subtypes. However, for 19 patients, novel subtypes were identified with <85% homology compared with previously described subtypes. These novel subtypes had the following genotypes: 9 in GT2, 5 in GT4, 2 in GT6, and 1 each in GT1, GT3, and GT5. Despite the presence of polymorphisms at resistance-associated substitution positions, 18 of the 19 patients treated with sofosbuvir-containing therapy achieved SVR12.
Conclusions: Nineteen novel HCV subtypes were identified, suggesting an even greater genetic diversity of HCV subtypes than previously recognized.
B-cell development and function depend on stage-specific signaling through the B-cell antigen receptor (BCR). Signaling and intracellular trafficking of the BCR are connected, but the molecular mechanisms of this link are incompletely understood. Here, we investigated the role of the endosomal adaptor protein and member of the LAMTOR/Ragulator complex LAMTOR2 (p14) in B-cell development. Efficient conditional deletion of LAMTOR2 at the pre-B1 stage using mb1-Cre mice resulted in complete developmental arrest. Deletion of LAMTOR2 using Cd19-Cre mice permitted analysis of residual B cells at later developmental stages, revealing that LAMTOR2 was critical for the generation and activation of mature B lymphocytes. Loss of LAMTOR2 resulted in aberrant BCR signaling due to delayed receptor internalization and endosomal trafficking. In conclusion, we identify LAMTOR2 as critical regulator of BCR trafficking and signaling that is essential for early B-cell development in mice.
Short Summary: Extracellular vesicles (EVs), released during tissue/cell injury, contain a "barcode" indicating specific microRNAs (miRs) that can uncover their origin. We examined whether systemic EVs possessing hepatic miR-signatures would indicate ongoing liver injury and clinical complications in trauma patients (TP). We grouped the patients of alcoholic drinkers into "alcohol-drinkers with liver injury (LI)" (EtOH with LI) or "alcohol-drinkers without LI" (EtOH w/o LI) and we compared these groups to "non-drinkers" (no EtOH). When we examined patient blood from the EtOH with LI group we found the total number of EVs to be increased, along with an increase in miR-122 and let7f—two EV-associated miRNAs—and several inflammation-associating cytokines, such as interleukin (IL)-6 and IL-33. In contrast, all of the aforementioned readouts were found to be decreased in the EtOH w/o LI group. These novel data demonstrate that hepatocyte damage in alcohol-intoxicated trauma patients presenting with liver injury can be reflected by an increase in circulating serum EVs, their specific miR-"barcode" and the concomitant increase of systemic inflammatory markers IL-6 and IL-33. Anti-inflammatory effect of alcohol-drinking in EtOH w/o LI can be presented by a reduced number of hepato-derived EVs, no upregulation of IL-6 and IL-33, and a miR "barcode" different from patients presenting with liver injury.
Background: Alcohol abuse is associated with (neuro)protective effects related to (head) injuries, and with negative effects regarding infection rates and survival in severely injured trauma patients (TP). Extracellular vesicles (EVs), which are released during tissue and/or cell injury, can contain a "barcode" including specific microRNAs (miRs) that uncover their origin. We examined whether EVs with a hepatic miR signature can be systemically measured, and whether they can indicate ongoing liver injury in alcohol-intoxicated TP and foretell clinical complications.
Patients/Methods: We enrolled 35 TP and measured blood EVs, IL-6, TNF-alpha, IL-1beta, IL-10 and IL-33, alcohol (ethanol, EtOH) concentration (BAC), GLDH, GGT, AST, ALT, leukocytes, platelets, and bilirubin. Within circulating EVs we measured the expression levels of miR-122, let7f, miR21, miR29a, miR-155, and miR-146a. Patients of alcohol-drinkers were grouped into "alcohol drinkers with liver injury (LI)" (EtOH with LI) or "alcohol drinkers without LI" (EtOH w/o LI) and compared to "non-drinkers" (no EtOH). We assessed systemic injury characteristics and the outcome of hospitalization with regard to sepsis, septic shock, pneumonia, or mortality.
Results: EtOH with LI patients had significantly increased rates of pneumonia vs. the EtOH w/o LI group. EVs, IL-6, and IL-33 levels were significantly increased in EtOH with LI vs. EtOH w/o LI group (p < 0.05). EV number correlated positively with ALT and IL-6 (p < 0.0001). Two miRs, miR-122 and let7f, were increased only in the blood EVs from the EtOH with LI group (p < 0.05). Five miRs, miR-122, let7f, miR-21, miR-29a, and miR-146a, were reduced in the blood EVs from the EtOH w/o LI group, vs. no EtOH (p < 0.05). Notably miR-122 correlated significantly with increased bilirubin levels in the EtOH with LI group (p < 0.05).
Conclusions: Liver injury in alcohol-intoxicated TP is reflected by increased EV numbers, their specific miR barcode, and the correlated increase of systemic inflammatory markers IL-6 and IL-33. Interestingly, severely injured TP without liver injury were found to have a reduced number of liver-derived EVs, no observed inflammatory infiltration and reduced specific miR "barcode."
Objectives: Large-scale clinical studies investigating associations between intestinal microbiota signatures and human diseases usually rely on stool samples. However, the timing of repeated stool sample collection cannot be predefined in longitudinal settings. Rectal swabs, being straightforward to obtain, have the potential to overcome this drawback. Therefore, we assessed the usability of rectal swabs for microbiome sampling in a cohort of hematological and oncological patients.
Study design: We used a pipeline for intestinal microbiota analysis from deep rectal swabs which was established and validated with test samples and negative controls. Consecutively, a cohort of patients from hematology and oncology wards was established and weekly deep rectal swabs taken during their admissions and re-admissions.
Results: Validation of our newly developed pipeline for intestinal microbiota analysis from rectal swabs revealed consistent and reproducible results. Over a period of nine months, 418 rectal swabs were collected longitudinally from 41 patients. Adherence to the intended sampling protocol was 97%. After DNA extraction, sequencing, read pre-processing and filtering of chimeric sequences, 405 of 418 samples (96.9%) were eligible for further analyses. Follow-up samples and those taken under current antibiotic exposure showed a significant decrease in alpha diversity as compared to baseline samples. Microbial domination occurred most frequently by Enterococcaceae (99 samples, 24.4%) on family level and Enterococcus (90 samples, 22.2%) on genus level. Furthermore, we noticed a high abundance of potential skin commensals in 99 samples (24.4%).
Summary: Deep rectal swabs were shown to be reliable for microbiome sampling and analysis, with practical advantages related to high sampling adherence, easy timing, transport and storage. The relatively high abundance of putative skin commensals in this patient cohort may be of potential interest and should be further investigated. Generally, previous findings on alpha diversity dynamics obtained from stool samples were confirmed.
Tolerizing CTL by sustained hepatic PD-L1 expression provides a new therapy spproach in mouse sepsis
(2019)
Cytotoxic T lymphocyte (CTL) activation contributes to liver damage during sepsis, but the mechanisms involved are largely unknown. Understanding the underlying principle will permit interference with CTL activation and thus, provide a new therapeutic option.
Methods: To elucidate the mechanism leading to CTL activation we used the Hepa1-6 cell line in vitro and the mouse model of in vivo polymicrobial sepsis, following cecal-ligation and -puncture (CLP) in wildtype, myeloid specific NOX-2, global NOX2 and NOX4 knockout mice, and their survival as a final readout. In this in vivo setting, we also determined hepatic mRNA and protein expression as well as clinical parameters of liver damage - aspartate- and alanine amino-transaminases. Hepatocyte specific overexpression of PD-L1 was achieved in vivo by adenoviral infection and transposon-based gene transfer using hydrodynamic injection.
Results: We observed downregulation of PD-L1 on hepatocytes in the murine sepsis model. Adenoviral and transposon-based gene transfer to restore PD-L1 expression, significantly improved survival and reduced the release of liver damage, as PD-L1 is a co-receptor that negatively regulates T cell function. Similar protection was observed during pharmacological intervention using recombinant PD-L1-Fc. N-acetylcysteine blocked the downregulation of PD-L1 suggesting the involvement of reactive oxygen species. This was confirmed in vivo, as we observed significant upregulation of PD-L1 expression in NOX4 knockout mice, following sham operation, whereas its expression in global as well as myeloid lineage NOX2 knockout mice was comparable to that in the wild type animals. PD-L1 expression remained high following CLP only in total NOX2 knockouts, resulting in significantly reduced release of liver damage markers.
Conclusion: These results suggest that, contrary to common assumption, maintaining PD-L1 expression on hepatocytes improves liver damage and survival of mice during sepsis. We conclude that administering recombinant PD-L1 or inhibiting NOX2 activity might offer a new therapeutic option in sepsis.
Curcumin—a rhizomal phytochemical from the plant Curcuma longa—is well known to inhibit cell proliferation and to induce apoptosis in a broad range of cell lines. In previous studies we showed that combining low curcumin concentrations and subsequent ultraviolet A radiation (UVA) or VIS irradiation induced anti-proliferative and pro-apoptotic effects. There is still debate whether curcumin induces apoptosis via the extrinsic or the intrinsic pathway. To address this question, we investigated in three epithelial cell lines (HaCaT, A431, A549) whether the death receptors CD95, tumor necrosis factor (TNF)-receptor I and II are involved in apoptosis induced by light and curcumin. Cells were incubated with 0.25–0.5 µg/mL curcumin followed by irradiation with 1 J/cm2 UVA. This treatment was combined with inhibitors specific for distinct membrane-bound death receptors. After 24 h apoptosis induction was monitored by quantitative determination of cytoplasmic histone-associated-DNA-fragments. Validation of our test system showed that apoptosis induced by CH11 and TNF-α could be completely inhibited by their respective antagonists. Interestingly, apoptosis induced by curcumin/light treatment was reversed by none of the herein examined death receptor antagonists. These results indicate a mechanism of action independent from classical death receptors speaking for intrinsic activation of apoptosis. It could be speculated that a shift in cellular redox balance might prompt the pro-apoptotic processes
Influence of structured reporting of tooth-colored indirect restorations on clinical decision-making
(2019)
The aim of the present study was to discover what influence structured reporting (study group = A) of toothcoloured lab-fabricated restorations has on clinical decision-making following international guidelines. By way of comparison, the conventional approach in the form of short reporting with 5 items (control group = B) was used as gold standard. The study was carried out in the first clinical semester of dentistry (n = 68) at the Goethe University in Frankfurt am Main. In the study group, indirect ceramic restorations were assessed on a scale of 1 (very good) to 5 (insufficient) using structured reporting (7 items, each with 5 subgroups) in accordance to World Dental Federation (FDI) - standards. Following this, the clinical decision on the insertion of the restoration was made. To evaluate the quality of the structured reporting, sensitivity, specificity, confidence intervals (Cl) and the respective predictive values (positive = PPV, negative= NPV) were determined. Based on FDI reporting, a ceramic inlay is also favored with a great degree of certainty in clinical decisions: this was the true in 34 procedures out of a total of 38 clinically incorporated ceramic inlays [sensitivity 67% (95% CI: 46%83%); specificity 89% (95% Cl: 75%-97%); PPV 82%, NPV 79%]. In the control group, sensitivity was 56% (95% CI: 35%-75%); specificity 92% (95% CI: 79%-98%); PPV 83%, NPV 74%. No significant differences could be determined between A and B (p = 0.813).
Due to the higher sensitivity and efficiency given comparable specificity, structured reporting of tooth-coloured lab-fabricated restorations based on FDI criteria, appears more recommendable than short reporting. It is also suitable for promoting decision-making in quality assessment, thus improving the durability of dental restorations.
The anti-cancer properties of curcumin in vitro have been documented. However, its clinical use is limited due to rapid metabolization. Since irradiation of curcumin has been found to increase its anti-cancer effect on several tumor types, this investigation was designed to determine whether irradiation with visible light may enhance the anti-tumor effects of low-dosed curcumin on renal cell carcinoma (RCC) cell growth and proliferation. A498, Caki1, and KTCTL-26 cells were incubated with curcumin (0.1–0.4 µg/mL) and irradiated with 1.65 J/cm2 visible light for 5 min. Controls were exposed to curcumin or light alone or remained untreated. Curcumin plus light, but not curcumin or light exposure alone altered growth, proliferation, and apoptosis of all three RCC tumor cell lines. Cells were arrested in the G0/G1 phase of the cell cycle. Phosphorylated (p) CDK1 and pCDK2, along with their counter-receptors Cyclin B and A decreased, whereas p27 increased. Akt-mTOR-signaling was suppressed, the pro-apoptotic protein Bcl-2 became elevated, and the anti-apoptotic protein Bax diminished. H3 acetylation was elevated when cells were treated with curcumin plus light, pointing to an epigenetic mechanism. The present findings substantiate the potential of combining low curcumin concentrations and light as a new therapeutic concept to increase the efficacy of curcumin in RCC.
Based on accumulating evidence of a role of lipid signaling in many physiological and pathophysiological processes including psychiatric diseases, the present data driven analysis was designed to gather information needed to develop a prospective biomarker, using a targeted lipidomics approach covering different lipid mediators. Using unsupervised methods of data structure detection, implemented as hierarchal clustering, emergent self-organizing maps of neuronal networks, and principal component analysis, a cluster structure was found in the input data space comprising plasma concentrations of d = 35 different lipid-markers of various classes acquired in n = 94 subjects with the clinical diagnoses depression, bipolar disorder, ADHD, dementia, or in healthy controls. The structure separated patients with dementia from the other clinical groups, indicating that dementia is associated with a distinct lipid mediator plasma concentrations pattern possibly providing a basis for a future biomarker. This hypothesis was subsequently assessed using supervised machine-learning methods, implemented as random forests or principal component analysis followed by computed ABC analysis used for feature selection, and as random forests, k-nearest neighbors, support vector machines, multilayer perceptron, and naïve Bayesian classifiers to estimate whether the selected lipid mediators provide sufficient information that the diagnosis of dementia can be established at a higher accuracy than by guessing. This succeeded using a set of d = 7 markers comprising GluCerC16:0, Cer24:0, Cer20:0, Cer16:0, Cer24:1, C16 sphinganine, and LacCerC16:0, at an accuracy of 77%. By contrast, using random lipid markers reduced the diagnostic accuracy to values of 65% or less, whereas training the algorithms with randomly permuted data was followed by complete failure to diagnose dementia, emphasizing that the selected lipid mediators were display a particular pattern in this disease possibly qualifying as biomarkers.
Compartmentalization of immune response and microbial translocation in decompensated cirrhosis
(2019)
Background: Acquired dysfunctional immunity in cirrhosis predisposes patients to frequent bacterial infections, especially spontaneous bacterial peritonitis (SBP), leading to systemic inflammation that is associated with poor outcome. But systemic inflammation can also be found in the absence of a confirmed infection. Detection of bacterial DNA has been investigated as a marker of SBP and as a predictor of prognosis. Data is, however, contradictory. Here we investigated whether levels of IL-6 and IL-8 putatively produced by myeloid cells in ascites are associated with systemic inflammation and whether inflammation depends on the presence of specific bacterial DNA.
Methods and Materials: We enrolled 33 patients with decompensated liver cirrhosis from whom we collected paired samples of blood and ascites. IL-6 and IL-8 were measured in serum samples of all patients using ELISA. In a subset of 10 representative patients, bacterial DNA was extracted from ascites and whole blood, followed by 16S rRNA gene amplicon sequencing.
Results: There were significantly higher levels of IL-6 in ascites fluid compared to blood samples in all patients. Interestingly, IL-6 levels in blood correlated tightly with disease severity and surrogates of systemic inflammation, while IL-6 levels in ascites did not. Moreover, patients with higher blood CRP levels showed greater SBP prevalence compared to patients with lower levels, despite similar positive culture results. Bacterial richness was also significantly higher in ascites compared to the corresponding patient blood. We identified differences in microbial composition and diversity between ascites and blood, but no tight relationship with surrogates of systemic inflammation could be observed.
Discussion: In decompensated cirrhosis, markers of systemic inflammation and microbiota composition seem to be dysregulated in ascites and blood. While a relationship between systemic inflammation and microbiota composition seems to exist in blood, this is not the case for ascites in our hands. These data may suggest compartmentalization of the immune response and interaction of the latter with the microbiota especially in the blood compartment.
Background: By performing case management, general practitioners and health care assistants can provide additional benefits to their chronically ill patients. However, the economic effects of such case management interventions often remain unclear although how to manage the burden of chronic disease is a key question for policy-makers. This analysis aimed to compare the cost-effectiveness of 24 months of primary care case management for patients with a long-term indication for oral anticoagulation therapy with usual care.
Methods: This analysis is part of the cluster-randomized controlled Primary Care Management for Optimized Antithrombotic Treatment (PICANT) trial. A sample of 680 patients with German statutory health insurance was initially considered for the cost analysis (92% of all participants at baseline). Costs included all disease-related direct health care costs from the payer’s perspective (German statutory health insurers) plus case management costs for the intervention group. A-Quality Adjusted Life Year (QALY) measurement (EQ-5D-3 L instrument) was used to evaluate utility, and incremental cost-effectiveness ratio (ICER) to assess cost-effectiveness. Mean differences were calculated and displayed with 95%-confidence intervals (CI) from non-parametric bootstrapping (1000 replicates).
Results: N = 505 patients (505/680, 74%) were included in the cost analysis (complete case analysis with a follow-up after 12 and 24 months as well as information on cost and QALY). After two years, the mean difference of direct health care costs per patient (€115, 95% CI [− 201; 406]) and QALYs (0.03, 95% CI [− 0.04; 0.11]) in the two groups was small and not significant. The costs of case management in the intervention group caused mean total costs per patient in this group to rise significantly (mean difference €503, 95% CI [188; 794]). The ICER was €16,767 per QALY. Regardless of the willingness of insurers to pay per QALY, the probability of the intervention being cost-effective never rose above 70%.
Conclusions: A primary care case management for patients with a long-term indication for oral anticoagulation therapy improved QALYs compared to usual care, but was more costly. However, the results may help professionals and policy-makers allocate scarce health care resources in such a way that the overall quality of care is improved at moderate costs, particularly for chronically ill patients.
Trial registration: Current Controlled Trials ISRCTN41847489.
Introduction: Chronic heart failure (CHF) is a heterogeneous condition requiring complex treatment from diverse healthcare services. An increasingly holistic understanding of healthcare has resulted in contextual factors such as perceived quality of care, as well as patients’ acceptance, preferences and subjective expectations of health services, all gaining in importance. How patients with CHF experience the use of healthcare services has not been studied within the scope of a systematic review in a German healthcare context. The aim of this scoping review is therefore to review systematically the experiences of patients affected by CHF with healthcare services in Germany in the literature and to map the research foci. Further objectives are to identify gaps in evidence, develop further research questions and to inform decision makers concerned with improving healthcare of patients living with CHF.
Methods and analysis: This scoping review will be based on a broad search strategy involving systematic and comprehensive electronic database searches in MEDLINE, EMBASE, PsycINFO, PSYNDEX, CINAHL and Cochrane’s Database of Systematic Reviews, grey literature searches, as well as hand searches through reference lists and non-indexed key journals. The methodological procedure will be based on an established six-stage framework for conducting scoping reviews that includes two independent reviewers. Data will be systematically extracted, qualitatively and quantitatively analysed and summarised both narratively and visually. To ensure the research questions and extracted information are meaningful, a patient representative will be involved.
Ethics and dissemination: Ethical approval will not be required to conduct this review. Results will be disseminated through a clearly illustrated report that will be part of a wider research project. Furthermore, it is intended that the review’s findings should be made available to relevant stakeholders through conference presentations and publication in peer-reviewed journals (knowledge transfer). Protocol registration in PROSPERO is not applicable for scoping reviews.
Glioblastoma (GBM), WHO grade IV, is the most aggressive primary brain tumor in adults. The median survival time using standard therapy is only 12–15 months with a 5-year survival rate of around 5%. Thus, new and effective treatment modalities are of significant importance. Signal transducer and activator of transcription 3 (Stat3) is a key signaling protein driving major hallmarks of cancer and represents a promising target for the development of targeted glioblastoma therapies. Here we present data showing that the therapeutic application of siRNAs, formulated in nanoscale lipopolyplexes (LPP) based on polyethylenimine (PEI) and the phospholipid 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), represents a promising new approach to target Stat3 in glioma. We demonstrate that the LPP-mediated delivery of siRNA mediates efficient knockdown of Stat3, suppresses Stat3 activity and limits cell growth in murine (Tu2449) and human (U87, Mz18) glioma cells in vitro. In a therapeutic setting, intracranial application of the siRNA-containing LPP leads to knockdown of STAT3 target gene expression, decreased tumor growth and significantly prolonged survival in Tu2449 glioma-bearing mice compared to negative control-treated animals. This is a proof-of-concept study introducing PEI-based lipopolyplexes as an efficient strategy for therapeutically targeting oncoproteins with otherwise limited druggability.
A case of Lymphangioleiomyomatosis (LAM) of the lung in a patient with a history of breast cancer
(2019)
Background: Lymphangioleiomyomatosis (LAM) is a rare progressive cystic and nodular disease of the lung characterized by smooth muscle cell proliferation. LAM predominantly affects young premenopausal women. This report is of a case of LAM presenting in a 47-year-old woman with a past history of breast cancer and discusses the possibility of an association between the two conditions.
Case report: A 47-year-old woman presented as an emergency with an exacerbation of a four-month history of shortness of breath and dry cough. Her symptoms began following the start of anti-hormonal treatment with letrozole and goserelin acetate for a moderately differentiated (grade 2) invasive ductal carcinoma of the breast (pT2, pN0, M0) which was positive for expression of estrogen receptor (ER+), progesterone receptor (PR+), and human epidermal growth factor receptor 2 (HER2+). Until the previous four months, she had breast-conserving treatment with radiotherapy and tamoxifen therapy. Following hospital admission, she was found to be in type I respiratory failure. Chest X-ray, lung computed tomography (CT), and positron-emission tomography (PET) showed diffuse cystic and nodular lung lesions, consistent with a diagnosis of LAM, and antihormonal therapy was discontinued. She developed pericarditis that was treated with the anti-inflammatory agent, colchicine. Treatment with letrozole and sirolimus improved her respiratory symptoms.
Conclusions: A rare case of LAM is presented in a woman with a recent history of breast cancer. Because both tumors were hormone-dependent, this may support common underlying gene associations and signaling pathways between the two types of tumor.
This study aims to elaborate the relevance of trauma severity and traumatic injury pattern in different multiple and/or polytrauma models by comparing five singular trauma to two different polytrauma (PT) models with high and one multiple trauma (MT) model with low injury-severity score (ISS). The aim is to provide a baseline for reducing animal harm according to 3Rs by providing less injury as possible in polytrauma modeling. Mice were randomly assigned to 10 groups: controls (Ctrl; n = 15), Sham (n = 15); monotrauma groups: hemorrhagic shock (HS; n = 15), thoracic trauma (TxT; n = 18), osteotomy with external fixation (Fx; n = 16), bilateral soft tissue trauma (bSTT; n = 16) or laparotomy (Lap; n = 16); two PT groups: PT I (TxT + HS + Fx; ISS = 18; n = 18), PT II (TxT + HS + Fx + Lap; ISS = 22; n = 18), and a MT group (TxT + HS + bSTT + Lap, ISS = 13; n = 18). Activity and mortality were assessed. Blood gas analyses and organ damage markers were determined after 6 h. Significant mortality occurred in TxT, PT and MT (11.7%). Activity decreased significantly in TxT, HS, both polytrauma and MT vs. Ctrl/Sham. PT-groups and MT had significantly decreased activity vs. bsTT, Lap or Fx. MT had significantly lower pCO2 vs. Ctrl/Sham, Lap or bsTT. Transaminases increased significantly in PT-groups and MT vs. Ctrl, Sham or monotrauma. Traumatic injury pattern is of comparable relevance as injury severity for experimental multiple or (poly)trauma modeling.
Up to 50% of patients initially treated for prostate cancer in a curative intent experience biochemical recurrence, possibly requiring adjuvant treatment. However, salvage treatment decisions, such as lymph node dissection or radiation therapy, are typically based on prostate specific antigen (PSA) recurrence. Importantly, common imaging modalities (e.g., computed tomography [CT], magnetic resonance imaging, and bone scan) are limited and the detection of recurrent disease is particularly challenging if PSA is low. Prostate specific membrane antigen (PSMA) positron-emission tomography/computed tomography (PET/CT) is a novel and promising imaging modality which aims to overcome the incapability of early identification of distant and regional metastases. Within this review, we summarize the current evidence related to PSMA-PET/CT in prostate cancer men diagnosed with biochemical recurrence after local treatment with curative intent. We discuss detection rates of PSMA-PET/CT stratified by PSA-levels and its impact on clinical decision making. Furthermore, we compare different imagefusion techniques such as PSMA-PET vs. F-/C-Choline-PET scans vs. PSMA-single photon emission computed tomography/CT. Finally, we touch upon the contemporary role of radio-guided-PSMA salvage lymphadenectomy.
After removal of a dental implant or extraction of a tooth in the upper jaw, the closure of an oroantral fistula (OAF) or oroantral communication (OAC) can be a difficult problem confronting the dentist and surgeon working in the oral and maxillofacial region. Oroantral communication (OAC) acts as a pathological pathway for bacteria and can cause infection of the antrum, which further obstructs the healing process as it is an unnatural communication between the oral cavity and the maxillary sinus. There are different ways to perform the surgical closure of the OAC. The decision-making in closure of oroantral communication and fistula is influenced by many factors. Consequently, it requires a combination of knowledge, experience, and information gathering. Previous narrative research has focused on assessments and comparisons of various surgical techniques for the closure of OAC/OAF. Thus, the decision-making process has not yet been described comprehensively.
The present study aims to illustrate all the factors that have to be considered in the management of OACs and OAFs that determine optimal treatment.
Purpose: Prisoners have a higher risk of suicide compared to non-incarcerated individuals. One aim of suicide prevention for prisoners is to identify risk factors in order to put stronger support mechanisms in place for the more vulnerable detainees. This study investigates the suicide risk (SR) in offence-related sub-populations in a representative German sample and differentiates between SR for adolescent and adult prisoners.
Methods: Conducting a national study with data from public German records on the entire prison population from 2000 to 2016 and suicide numbers in German prisons in the same period, SR was calculated for the total male prison population as well as for both subgroups, adolescent and adult male prisoners.
Results: In the study period, male prisoners spent 959.584 life years (LY) in German criminal detention. Among those, 524 prisoners died of suicide. SR was higher for detainees imprisoned for an offence resulting in extensive physical harm for another person, e.g. homicide (suicide rate = 134,8 suicides per 100.000 LY; OR = 2,47; CI95%: 1,98–3,08), bodily injury (suicide rate = 87,3; OR = 1,60; CI95%: 1,29–1,99), and sexual offences (suicide rate = 84,2; OR = 1,54; CI95%: 1,18–2,01) compared with the SR of the total prison population (suicide rate = 54.6). Age differences between offence-related SR were found for theft, with adolescents (suicide rate = 69,3; OR = 1,25; CI95%: 0,85–1,84) showing higher SR than adults (suicide rate = 38,2; OR = 0,7; CI95%: 0,54–0,92).
Conclusion: The index offence of detainees is associated with SR and age-related differences exist. Suicide prevention in prisons should take both into account to determine populations at risk.
Synthesis and SAR of the antistaphylococcal natural product nematophin from Xenorhabdus nematophila
(2019)
The repeated and improper use of antibiotics had led to an increased number of multiresistant bacteria. Therefore, new lead structures are needed. Here, the synthesis and an expanded structure–activity relationship of the simple and antistaphylococcal amide nematophin from Xenorhabdus nematophila and synthetic derivatives are described. Moreover, the synthesis of intrinsic fluorescent derivatives, incorporating azaindole moieties was achieved for the first time.
Background: While the incidence and aspects of pneumonia in ICU patients has been extensively discussed in the literature, studies on the occurrence of pneumonia in severely injured patients are rare. The aim of the present study is to elucidate factors associated with the occurrence of pneumonia in severely injured patients with thoracic trauma.
Setting: Level-I University Trauma Centres associated with the TraumaRegister DGU®.
Methods: A total of 1162 severely injured adult patients with thoracic trauma documented in the TraumaRegister DGU® (TR-DGU) were included in this study. Demographic data, injury severity, duration of mechanical ventilation (MV), duration of ICU stay, occurrence of pneumonia, bronchoalveolar lavage, aspiration, pathogen details, and incidences of mortality were evaluated. Statistical evaluation was performed using SPSS (Version 25.0, SPSS, Inc.) software.
Results: The overall incidence of pneumonia was 27.5%. Compared to patients without pneumonia, patients with pneumonia had sustained more severe injuries (mean ISS: 32.6 vs. 25.4), were older (mean age: 51.3 vs. 47.5) and spent longer periods under MV (mean: 368.9 h vs. 114.9 h). Age, sex (male), aspiration, and duration of MV were all independent predictors for pneumonia occurrence in a multivariate analysis. The cut-off point for duration of MV that best discriminated between patients who would and would not develop pneumonia during their hospital stay was 102 h. The extent of thoracic trauma (AISthorax), ISS, and presence of pulmonary comorbidities did not show significant associations to pneumonia incidence in our multivariate analysis. No significant difference in mortality between patients with and without pneumonia was observed.
Conclusions: Likelihood of pneumonia increases with age, aspiration, and duration of MV. These parameters were not found to be associated with differences in outcomes between patients with and without pneumonia. Future studies should focus on independent parameters to more clearly identify severely injured subgroups with a high risk of developing pneumonia.
Level of evidence: Level II - Retrospective medical record review.
Glioblastoma is one of the deadliest malignancies and is virtually incurable. Accumulating evidence indicates that a small population of cells with a stem-like phenotype is the major culprit of tumor recurrence. Enhanced DNA repair capacity and expression of stemness marker genes are the main characteristics of these cells. Elimination of this population might delay or prevent tumor recurrence following radiochemotherapy. The aim of this study was to analyze whether interference with the Hedgehog signaling (Hh) pathway or combined Hh/Notch blockade using small-molecule inhibitors can efficiently target these cancer stem cells and sensitize them to therapy. Using tumor sphere lines and primary patient-derived glioma cultures we demonstrate that the Hh pathway inhibitor GANT61 (GANT) and the arsenic trioxide (ATO)-mediated Hh/Notch inhibition are capable to synergistically induce cell death in combination with the natural anticancer agent (−)-Gossypol (Gos). Only ATO in combination with Gos also strongly decreased stemness marker expression and prevented sphere formation and recovery. These synergistic effects were associated with distinct proteomic changes indicating diminished DNA repair and markedly reduced stemness. Finally, using an organotypic brain slice transplantation model, we show that combined ATO/Gos treatment elicits strong growth inhibition or even complete elimination of tumors. Collectively, our data show for the first time that ATO and Gos, two drugs that can be used in the clinic, represent a promising targeted therapy approach for the synergistic elimination of glioma stem-like cells.
Current technologies used to generate CRISPR/Cas gene perturbation reagents are labor intense and require multiple ligation and cloning steps. Furthermore, increasing gRNA sequence diversity negatively affects gRNA distribution, leading to libraries of heterogeneous quality. Here, we present a rapid and cloning-free mutagenesis technology that can efficiently generate covalently-closed-circular-synthesized (3Cs) CRISPR/Cas gRNA reagents and that uncouples sequence diversity from sequence distribution. We demonstrate the fidelity and performance of 3Cs reagents by tailored targeting of all human deubiquitinating enzymes (DUBs) and identify their essentiality for cell fitness. To explore high-content screening, we aimed to generate the largest up-to-date gRNA library that can be used to interrogate the coding and noncoding human genome and simultaneously to identify genes, predicted promoter flanking regions, transcription factors and CTCF binding sites that are linked to doxorubicin resistance. Our 3Cs technology enables fast and robust generation of bias-free gene perturbation libraries with yet unmatched diversities and should be considered an alternative to established technologies.
Discovery of key whole-brain transitions and dynamics during human wakefulness and non-REM sleep
(2019)
The modern understanding of sleep is based on the classification of sleep into stages defined by their electroencephalography (EEG) signatures, but the underlying brain dynamics remain unclear. Here we aimed to move significantly beyond the current state-of-the-art description of sleep, and in particular to characterise the spatiotemporal complexity of whole-brain networks and state transitions during sleep. In order to obtain the most unbiased estimate of how whole-brain network states evolve through the human sleep cycle, we used a Markovian data-driven analysis of continuous neuroimaging data from 57 healthy participants falling asleep during simultaneous functional magnetic resonance imaging (fMRI) and EEG. This Hidden Markov Model (HMM) facilitated discovery of the dynamic choreography between different whole-brain networks across the wake-non-REM sleep cycle. Notably, our results reveal key trajectories to switch within and between EEG-based sleep stages, while highlighting the heterogeneities of stage N1 sleep and wakefulness before and after sleep.
Background: Peritonitis is responsible for thousands of deaths annually in Germany alone. Even source control (SC) and antibiotic treatment often fail to prevent severe sepsis or septic shock, and this situation has hardly improved in the past two decades. Most experimental immunomodulatory therapeutics for sepsis have been aimed at blocking or dampening a specific pro-inflammatory immunological mediator. However, the patient collective is large and heterogeneous. There are therefore grounds for investigating the possibility of developing personalized therapies by classifying patients into groups according to biomarkers. This study aims to combine an assessment of the efficacy of treatment with a preparation of human immunoglobulins G, A, and M (IgGAM) with individual status of various biomarkers (immunoglobulin level, procalcitonin, interleukin 6, antigen D-related human leucocyte antigen (HLA-DR), transcription factor NF-κB1, adrenomedullin, and pathogen spectrum).
Methods/design: A total of 200 patients with sepsis or septic shock will receive standard-of-care treatment (SoC). Of these, 133 patients (selected by 1:2 randomization) will in addition receive infusions of IgGAM for 5 days. All patients will be followed for approximately 90 days and assessed by the multiple-organ failure (MOF) score, by the EQ QLQ 5D quality-of-life scale, and by measurement of vital signs, biomarkers (as above), and survival.
Discussion: This study is intended to provide further information on the efficacy and safety of treatment with IgGAM and to offer the possibility of correlating these with the biomarkers to be studied. Specifically, it will test (at a descriptive level) the hypothesis that patients receiving IgGAM who have higher inflammation status (IL-6) and poorer immune status (low HLA-DR, low immunoglobulin levels) have a better outcome than patients who do not receive IgGAM. It is expected to provide information that will help to close the knowledge gap concerning the association between the effect of IgGAM and the presence of various biomarkers, thus possibly opening the way to a personalized medicine.
Trial registration: EudraCT, 2016–001788-34; ClinicalTrials.gov, NCT03334006. Registered on 17 Nov 2017.
Trial sponsor: RWTH Aachen University, represented by the Center for Translational & Clinical Research Aachen (contact Dr. S. Isfort).
During the past 15 years there have been dramatic changes in the medical landscape, particularly in oncology and regenerative medicine. Cell therapies have played a substantial part in this progress. Cellular immunotherapies can use immune cells, such as T cells or natural killer cells that, after functional modification ex vivo, exert powerful anti-cancer effects when given to the patient. Innovative technologies, such as re-programming terminally differentiated cells into pluripotent stem cells or into other cell types and applying specific enzymes to more precisely edit the human genome, are paving the way towards more potent cell and gene therapies.
Mesenchymal stromal cells are promising cellular immunotherapeutics, which also have potential for use in tissue engineering strategies and other regenerative medicine applications. However, substantial gaps in our knowledge of their biology and therapeutic efficacy present major challenges to their sustainable implementation in the clinical routine.
In this article, progress in the field of cell therapeutics during the past 15 years will be briefly discussed, with a focus on mesenchymal stromal cells, highlighting the impact of this field on patient care.
Memory impairments are a major characteristic of schizophrenia (SZ). In the current study, we used an associative memory task to test the hypothesis that SZ patients and first-degree relatives have altered functional patterns in comparison to healthy controls. We analyzed the fMRI activation pattern during the presentation of a face-name task in 27 SZ patients, 23 first-degree relatives, and 27 healthy controls. In addition, we performed correlation analyses between individual psychopathology, accuracy and reaction time of the task and the beta scores of the functional brain activations. We observed a lower response accuracy and increased reaction time during the retrieval of face-name pairs in SZ patients compared with controls. Deficient performance was accompanied by abnormal functional activation patterns predominantly in DMN regions during encoding and retrieval. No significant correlation between individual psychopathology and neuronal activation during encoding or retrieval of face-name pairs was observed. Findings of first-degree relatives indicated slightly different functional pattern within brain networks in contrast to controls without significant differences in the behavioral task. Both the accuracy of memory performance as well as the functional activation pattern during retrieval revealed alterations in SZ patients, and, to a lesser degree, in relatives. The results are of potential relevance for integration within a comprehensive model of memory function in SZ. The development of a neurophysiological model of cognition in psychosis may help to clarify and improve therapeutic options to improve memory and functioning in the illness.
Numerous cell–cell and cell–matrix interactions within the bone marrow microenvironment enable the controlled lifelong self-renewal and progeny of hematopoietic stem and progenitor cells (HSPCs). On the cellular level, this highly mutual interaction is granted by cell adhesion molecules (CAMs) integrating differentiation, proliferation, and pro-survival signals from the surrounding microenvironment to the inner cell. However, cell–cell and cell–matrix interactions are also critically involved during malignant transformation of hematopoietic stem/progenitor cells. It has become increasingly apparent that leukemia-associated gene products, such as activated tyrosine kinases and fusion proteins resulting from chromosomal translocations, directly regulate the activation status of adhesion molecules, thereby directing the leukemic phenotype. These observations imply that interference with adhesion molecule function represents a promising treatment strategy to target pre-leukemic and leukemic lesions within the bone marrow niche. Focusing on myeloid leukemia, we provide a current overview of the mechanisms by which leukemogenic gene products hijack control of cellular adhesion to subsequently disturb normal hematopoiesis and promote leukemia development.
Background: Posaconazole (POS) is a potent triazole antifungal agent approved in adults for treatment and prophylaxis of invasive fungal infections (IFIs). The objectives of this study were to evaluate the pharmacokinetics (PK), safety, and tolerability of POS oral suspension in pediatric subjects with neutropenia.
Methods: This was a prospective, multicenter, sequential dose-escalation study. Enrolled subjects were divided into 3 age groups: AG1, 7 to <18 years; AG2, 2 to <7 years; and AG3, 3 months to <2 years. AG1 and AG2 were divided into 3 dosage cohorts: DC1, 12 mg/kg/day divided twice daily (BID); DC2, 18 mg/kg/day BID; and DC3, 18 mg/kg/day divided thrice daily (TID). AG3 was also divided into DC1 and DC2; however, no subjects were enrolled in DC2. Subjects received 7–28 days of POS oral suspension. PK samples were collected at predefined time points. The POS PK target was predefined as ~90% of subjects with Cavg (AUC /dosing interval) between 500 and 2500 ng/mL, with an anticipated mean steady state Cavg exposure of ~1200 ng/mL.
Results: The percentage of subjects meeting the PK target was <90% across all age groups and dosage cohorts (range: 31% to 80%). The percentage of subjects that achieved the Cavg target of 500 to 2500 ng/mL on Day 7 ranged from 31% to 80%, with the lowest proportion in subjects 2 to <7 years receiving 12 mg/kg/day BID (AG2/DC1) and the highest proportion in subjects 7 to <18 years receiving 18 mg/kg/day TID (AG1/DC3). At all three dose levels (12 mg/kg/day BID, 18 mg/kg/day BID and 18 mg/kg/day TID), subjects in AG1 (7 to <18 years old) had higher mean PK exposures at steady state than those in AG2. High variability in exposures was observed in all groups. POS oral suspension was generally well tolerated and most of the reported adverse events were related to the subjects’ underlying diseases.
Conclusion: The POS PK target of 90% of subjects with Cavg between 500 and 2500 ng/mL was not achieved in any of the age groups across the different dosage cohorts. New formulations of the molecule with a greater potential to achieve the established PK target are currently under investigation.
Trial registration: ClinicalTrials.gov identifier: NCT01716234
Purpose: To review the role of radiotherapy (RT) in the treatment of renal cell cancer (RCC) in the curative and palliative setting.
Content: Details related to the clinical outcomes of primary, preoperative, postoperative and palliative RT are discussed, along with a presentation of the established role of surgery and systemic therapy. An overview of data derived from mono- and multi-institutional trials is provided.
Conclusion: Radiotherapy has been shown to provide good symptom palliation and local control in RCC depending on the dose that can be delivered. There is emerging data suggesting that with the use of high-precision RT methods the indication spectrum of RT can be exploited covering different clinical situations particularly for unresectable local recurrences and oligometastatic disease.
The interdependence of selective cues during development of regulatory T cells (Treg cells) in the thymus and their suppressive function remains incompletely understood. Here, we analyzed this interdependence by taking advantage of highly dynamic changes in expression of microRNA 181 family members miR-181a-1 and miR-181b-1 (miR-181a/b-1) during late T-cell development with very high levels of expression during thymocyte selection, followed by massive down-regulation in the periphery. Loss of miR-181a/b-1 resulted in inefficient de novo generation of Treg cells in the thymus but simultaneously permitted homeostatic expansion in the periphery in the absence of competition. Modulation of T-cell receptor (TCR) signal strength in vivo indicated that miR-181a/b-1 controlled Treg-cell formation via establishing adequate signaling thresholds. Unexpectedly, miR-181a/b-1–deficient Treg cells displayed elevated suppressive capacity in vivo, in line with elevated levels of cytotoxic T-lymphocyte–associated 4 (CTLA-4) protein, but not mRNA, in thymic and peripheral Treg cells. Therefore, we propose that intrathymic miR-181a/b-1 controls development of Treg cells and imposes a developmental legacy on their peripheral function.
In the current study we compared the molecular signature of expanded mesenchymal stromal cells (MSCs) derived from selected CD271+ bone marrow mononuclear cells (CD271-MSCs) and MSCs derived from non-selected bone marrow mononuclear cells by plastic adherence (PA-MSCs). Transcriptome analysis demonstrated for the first time the upregulation of 115 and downregulation of 131 genes in CD271-MSCs. Functional enrichment analysis showed that the upregulated genes in CD271-MSCs are significantly enriched for extracellular matrix (tenascin XB, elastin, ABI family, member 3 (NESH) binding protein, carboxypeptidase Z, laminin alpha 2 and nephroblastoma overexpressed) and cell adhesion (CXCR7, GPNMB, MYBPH, SVEP1, ARHGAP6, TSPEAR, PIK3CG, ABL2 and NCAM1). CD271-MSCs expressed higher gene transcript levels that are involved in early osteogenesis/chondrogenesis/adipogenesis (ZNF145, FKBP5). In addition, increased transcript levels for early and late osteogenesis (DPT, OMD, ID4, CRYAB, SORT1), adipogenesis (CTNNB1, ZEB, LPL, FABP4, PDK4, ACDC), and chondrogenesis (CCN3/NOV, CCN4/WISP1, CCN5/WISP2 and ADAMTS-5) were detected. Interestingly, CD271-MSCs expressed increased levels of hematopoiesis associated genes (CXCL12, FLT3L, IL-3, TPO, KITL). Down-regulated genes in CD271-MSCs were associated with WNT and TGF-beta signaling, and cytokine/chemokine signaling pathways. In addition to their capacity to support hematopoiesis, these results suggest that CD271-MSCs may contain more osteo/chondro progenitors and/or feature a greater differentiation potential.
Background: Electrochemical signals play an important role in cell communication and behavior. Electrically charged ions transported across cell membranes maintain an electrochemical imbalance that gives rise to bioelectric signaling, called membrane potential or Vmem. Vmem plays a key role in numerous inter- and intracellular functions that regulate cell behaviors like proliferation, differentiation and migration, all playing a critical role in embryonic development, healing, and regeneration.
Methods: With the goal of analyzing the changes in Vmem during cell proliferation and differentiation, here we used direct current electrical stimulation (EStim) to promote cell proliferation and differentiation and simultaneously tracked the corresponding changes in Vmem in adipose derived mesenchymal stem cells (AT-MSC).
Results: We found that EStim caused increased AT-MSC proliferation that corresponded to Vmem depolarization and increased osteogenic differentiation that corresponded to Vmem hyperpolarization. Taken together, this shows that Vmem changes associated with EStim induced cell proliferation and differentiation can be accurately tracked during these important cell functions. Using this tool to monitor Vmem changes associated with these important cell behaviors we hope to learn more about how these electrochemical cues regulate cell function with the ultimate goal of developing new EStim based treatments capable of controlling healing and regeneration.
Hypoxia poses a stress to cells and decreases mitochondrial respiration, in part by electron transport chain (ETC) complex reorganization. While metabolism under acute hypoxia is well characterized, alterations under chronic hypoxia largely remain unexplored. We followed oxygen consumption rates in THP-1 monocytes during acute (16 h) and chronic (72 h) hypoxia, compared to normoxia, to analyze the electron flows associated with glycolysis, glutamine, and fatty acid oxidation. Oxygen consumption under acute hypoxia predominantly demanded pyruvate, while under chronic hypoxia, fatty acid- and glutamine-oxidation dominated. Chronic hypoxia also elevated electron-transferring flavoproteins (ETF), and the knockdown of ETF–ubiquinone oxidoreductase lowered mitochondrial respiration under chronic hypoxia. Metabolomics revealed an increase in citrate under chronic hypoxia, which implied glutamine processing to α-ketoglutarate and citrate. Expression regulation of enzymes involved in this metabolic shunting corroborated this assumption. Moreover, the expression of acetyl-CoA carboxylase 1 increased, thus pointing to fatty acid synthesis under chronic hypoxia. Cells lacking complex I, which experienced a markedly impaired respiration under normoxia, also shifted their metabolism to fatty acid-dependent synthesis and usage. Taken together, we provide evidence that chronic hypoxia fuels the ETC via ETFs, increasing fatty acid production and consumption via the glutamine-citrate-fatty acid axis.
Since Inhibitor of Apoptosis (IAP) proteins have been implicated in cellular adaptation to endoplasmic reticulum (ER) stress, we investigated the regulation of ER stress-induced apoptosis by small-molecule second mitochondria-derived activator of caspase (Smac) mimetics that antagonize IAP proteins. Here, we discover that Smac mimetic suppresses tunicamycin (TM)-induced apoptosis via resolution of the unfolded protein response (UPR) and ER stress. Smac mimetics such as BV6 selectively inhibit apoptosis triggered by pharmacological or genetic inhibition of protein N-glycosylation using TM or knockdown of DPAGT1, the enzyme that catalyzes the first step of protein N-glycosylation. In contrast, BV6 does not rescue cell death induced by other typical ER stressors (i.e., thapsigargin (TG), dithiothreitol, brefeldin A, bortezomib, or 2-deoxyglucose). The protection from TM-triggered apoptosis is found for structurally different Smac mimetics and for genetic knockdown of cellular IAP (cIAP) proteins in several cancer types, underlining the broader relevance. Interestingly, lectin microarray profiling reveals that BV6 counteracts TM-imposed inhibition of protein glycosylation. BV6 consistently abolishes TM-stimulated accumulation of ER stress markers such as glucose-regulated protein 78 (GRP78) and C/EBP homologous protein (CHOP) and reduces protein kinase RNA-like ER kinase (PERK) phosphorylation and X box-binding protein 1 (XBP1) splicing upon TM treatment. BV6-stimulated activation of nuclear factor-κB (NF-κB) contributes to the resolution of ER stress, since NF-κB inhibition by overexpression of dominant-negative IκBα superrepressor counteracts the suppression of TM-stimulated transcriptional activation of CHOP and GRP78 by BV6. Thus, our study is the first to show that Smac mimetic protects from TM-triggered apoptosis by resolving the UPR and ER stress. This provides new insights into the regulation of cellular stress responses by Smac mimetics.
Purpose: To analyze leg pain severity data from a randomized controlled trial (RCT) of lumbar disc surgery using integrated approaches that adjust pain scores collected at scheduled follow-up visits for confounding clinical events occurring between visits. Methods. Data were derived from an RCT of a bone-anchored annular closure device (ACD) following lumbar discectomy versus lumbar discectomy alone (Control) in patients with large postsurgical annular defects. Leg pain was recorded on a 0 to 100 scale at 6 weeks, 3 months, 6 months, 1 year, and 2 years of follow-up. Patients with pain reduction ≥20 points relative to baseline were considered responders. Unadjusted analyses utilized pain scores reported at follow-up visits. Since symptomatic reherniation signifies clinical failure of lumbar discectomy, integrated analyses adjusted pain scores following a symptomatic reherniation by baseline observation carried forward for continuous data or classification as nonresponders for categorical data.
Results: Among 550 patients (272 ACD, 278 Control), symptomatic reherniation occurred in 10.3% of ACD patients and in 21.9% of controls (p < 0.001) through 2 years. There was no difference in leg pain scores at the 2-year visit between ACD and controls (12 versus 14; p = 0.33) in unadjusted analyses, but statistically significant differences favoring ACD (19 versus 29; p < 0.001) in integrated analyses. Unadjusted nonresponder rates were 6.0% with ACD and 6.7% with controls (p = 0.89), but 15.7% and 27.8% (p = 0.001) in integrated analyses. The probability of nonresponse was 16.4% with ACD and 18.3% with controls (p = 0.51) in unadjusted analysis, and 23.7% and 31.2% (p = 0.04) in integrated analyses.
Conclusion: In an RCT of lumbar disc surgery, an integrated analysis of pain severity that adjusted for the confounding effects of clinical failures occurring between follow-up visits resulted in different conclusions compared to an unadjusted analysis of pain scores reported at follow-up visits only.
Background: Transcatheter aortic valve replacement (TAVR) is a therapeutic option for patients with aortic valve stenosis at increased surgical risk. Telomeres are an established marker for cellular senescence and have served to evaluate cardiovascular diseases including severe aortic valve stenosis. In our study, we hypothesized that telomere length may be a predictor for outcome and associated with comorbidities in patients with TAVR.
Methods and results: We analyzed leucocyte telomere length from 155 patients who underwent TAVR and correlated the results with 1-year mortality and severe comorbidities. The cohort was subdivided into 3 groups according to telomere length. Although a trend for a positive correlation of telomere length with a lower EuroSCORE could be found, telomere length was not associated with survival, aortic valve opening area or cardiovascular comorbidities (peripheral, coronary or cerebrovascular disease). Interestingly, long telomeres were significantly correlated to a reduced left ventricular ejection fraction (LVEF).
Conclusion: In elderly patients with severe aortic valve stenosis, leucocyte telomere length did not predict post-procedural survival. The correlation between long telomere length and reduced LVEF in these patients deserves further attention.
kurz und kn@pp news : Nr. 45
(2019)
Paclitaxel is a frontline drug for the treatment of epithelial ovarian cancer (EOC). However, following paclitaxel-platinum based chemotherapy, tumor recurrence occurs in most ovarian cancer patients. Chromosomal instability (CIN) is a hallmark of cancer and represents genetic variation fueling tumor adaptation to cytotoxic effects of anticancer drugs. In this study, our Kaplan-Meier analysis including 263 ovarian cancer patients (stages I/II) revealed that high Polo-like kinase (PLK) 1 expression correlates with bad prognosis. To evaluate the role of PLK1 as potential cancer target within a combinatorial trial, we induced strong mitotic arrest in ovarian cancer cell lines by synergistically co-targeting microtubules (paclitaxel) and PLK1 (BI6727) followed by pharmaceutical inhibition of the Anaphase-Promoting Complex (APC/C) using proTAME. In short- and long-term experiments, this triple treatment strongly activated apoptosis in cell lines and primary ovarian cells derived from cancer patients. Mechanistically, BI6727/paclitaxel/proTAME stabilize Cyclin B1 and trigger mitotic arrest, which initiates mitochondrial apoptosis by inactivation of antiapoptotic BCL-2 family proteins, followed by activation of caspase-dependent effector pathways. This triple treatment prevented endoreduplication and reduced CIN, two mechanisms that are associated with aggressive tumors and the acquisition of drug resistance. This “two-punch strategy” (strong mitotic arrest followed by blocking mitotic exit) has important implications for developing paclitaxel-based combinatorial treatments in ovarian cancer.
Background: The clinical presentation of gastroesophageal reflux disease (GERD) shows a large symptom variation also in different intensities among patients. As several studies have shown, there is a large overlap in the symptomatic spectrum between proven GERD and other disorders such as dyspepsia, functional heartburn and/or somatoform disorders.
Aim: To prospectively evaluate the GERD patients with and without somatoform disorders before and after laparoscopic antireflux surgery.
Methods: In a tertiary referral center for foregut surgery over a period of 3 years patients with GERD, qualifying for the indication of laparoscopic antireflux surgery, were investigated prospectively regarding their symptomatic spectrum in order to identify GERD and associated somatoform disorders. Assessment of symptoms was performed by an instrument for the evaluation of somatoform disorders [Somatoform Symptom Index (SSI) > 17]. Quality of life was evaluated by Gastrointestinal Quality of Life Index (GIQLI).
Results: In 123 patients an indication for laparoscopic antireflux surgery was established and in 43 patients further medical therapy was suggested. The portion of somatoform tendencies in the total patient population was 20.48% (34 patients). Patients with a positive SSI had a preoperative GIQLI of 77 (32-111). Patients with a normal SSI had a GIQLI of 105 (29-140) (P < 0.0001). In patients with GERD the quality of life could be normalized from preoperative reduced values of GIQLI 102 (47-140) to postoperative values of 117 (44-144). In patients with GERD and somatoform disorders, the GIQLI was improved from preoperative GIQLI 75 (47-111) to postoperative 95 (44-122) (P < 0.0043).
Conclusion: Patients with GERD and associated somatoform disorders have significantly worse levels of quality of life. The latter patients can also benefit from laparoscopic fundoplication, however they will not reach a normal level.
The TP53-induced glycolysis and apoptosis regulator (TIGAR) has been shown to decrease glycolysis, to activate the pentose phosphate pathway, and to provide protection against oxidative damage. Hypoxic regions are considered characteristic of glioblastoma and linked with resistance to current treatment strategies. Here, we established that LNT-229 glioma cell lines stably expressed shRNA constructs targeting TIGAR, and exposed them to hypoxia, irradiation and temozolomide. The disruption of TIGAR enhanced levels of reactive oxygen species and cell death under hypoxic conditions, as well as the effectiveness of irradiation and temozolomide. In addition, TIGAR was upregulated by HIF-1α. As a component of a complex network, TIGAR contributes to the metabolic adjustments that arise from either spontaneous or therapy-induced changes in tumor microenvironment.
Background: Here we examined myocardial microRNA (miRNA) expression profile in a sensory neuropathy model with cardiac diastolic dysfunction and aimed to identify key mRNA molecular targets of the differentially expressed miRNAs that may contribute to cardiac dysfunction. Methods: Male Wistar rats were treated with vehicle or capsaicin for 3 days to induce systemic sensory neuropathy. Seven days later, diastolic dysfunction was detected by echocardiography, and miRNAs were isolated from the whole ventricles. Results: Out of 711 known miRNAs measured by miRNA microarray, the expression of 257 miRNAs was detected in the heart. As compared to vehicle-treated hearts, miR-344b, miR-466b, miR-98, let-7a, miR-1, miR-206, and miR-34b were downregulated, while miR-181a was upregulated as validated also by quantitative real time polymerase chain reaction (qRT-PCR). By an in silico network analysis, we identified common mRNA targets (insulin-like growth factor 1 (IGF-1), solute carrier family 2 facilitated glucose transporter member 12 (SLC2a-12), eukaryotic translation initiation factor 4e (EIF-4e), and Unc-51 like autophagy activating kinase 2 (ULK-2)) targeted by at least three altered miRNAs. Predicted upregulation of these mRNA targets were validated by qRT-PCR. Conclusion: This is the first demonstration that sensory neuropathy affects cardiac miRNA expression network targeting IGF-1, SLC2a-12, EIF-4e, and ULK-2, which may contribute to cardiac diastolic dysfunction. These results further support the need for unbiased omics approach followed by in silico prediction and validation of molecular targets to reveal novel pathomechanisms.
Introduction: Colorectal cancers (CRCs) deficient in the DNA mismatch repair protein MutL homolog 1 (MLH1) display distinct clinicopathological features and require a different therapeutic approach compared to CRCs with MLH1 proficiency. However, the molecular basis of this fundamental difference remains elusive. Here, we report that MLH1-deficient CRCs exhibit reduced levels of the cytoskeletal scaffolding protein non-erythroid spectrin αII (SPTAN1), and that tumor progression and metastasis of CRCs correlate with SPTAN1 levels.
Methods and results: To investigate the link between MLH1 and SPTAN1 in cancer progression, a cohort of 189 patients with CRC was analyzed by immunohistochemistry. Compared with the surrounding normal mucosa, SPTAN1 expression was reduced in MLH1-deficient CRCs, whereas MLH1-proficient CRCs showed a significant upregulation of SPTAN1. Overall, we identified a strong correlation between MLH1 status and SPTAN1 expression. When comparing TNM classification and SPTAN1 levels, we found higher SPTAN1 levels in stage I CRCs, while stages II to IV showed a gradual reduction of SPTAN1 expression. In addition, SPTAN1 expression was lower in metastatic compared with non-metastatic CRCs. Knockdown of SPTAN1 in CRC cell lines demonstrated decreased cell viability, impaired cellular mobility and reduced cell-cell contact formation, indicating that SPTAN1 plays an important role in cell growth and cell attachment. The observed weakened cell-cell contact of SPTAN1 knockdown cells might indicate that tumor cells expressing low levels of SPTAN1 detach from their primary tumor and metastasize more easily.
Conclusion: Taken together, we demonstrate that MLH1 deficiency, low SPTAN1 expression, and tumor progression and metastasis are in close relation. We conclude that SPTAN1 is a candidate molecule explaining the tumor progression and metastasis of MLH1-deficient CRCs. The detailed analysis of SPTAN1 is now mandatory to substantiate its relevance and its potential value as a candidate protein for targeted therapy, and as a predictive marker of cancer aggressiveness.
Objectives: Combined electric-acoustic stimulation (EAS) is a well-accepted therapeutic treatment for cochlear implant (CI) users with residual hearing in the low frequencies but severe to profound hearing loss in the high frequencies. The recently introduced SONNETeas audio processor offers different microphone directionality (MD) settings and wind noise reduction (WNR) as front-end processing. The aim of this study was to compare speech perception in quiet and noise between two EAS audio processors DUET 2 and SONNETeas, to assess the impact of MD and WNR on speech perception in EAS users in the absence of wind. Furthermore, subjective rating of hearing performance was registered.
Method: Speech perception and subjective rating with SONNETeas or DUET 2 audio processor were assessed in 10 experienced EAS users. Speech perception was measured in quiet and in a diffuse noise setup (MSNF). The SONNETeas processor was tested with three MD settings omnidirectional/natural/adaptive and with different intensities of WNR. Subjective rating of auditory benefit and sound quality was rated using two questionnaires.
Results: There was no significant difference between DUET 2 and SONNETeas processor using the omnidirectional microphone in quiet and in noise. There was a significant improvement in SRT with MD settings natural (2.2 dB) and adaptive (3.6 dB). No detrimental effect of the WNR algorithm on speech perception was found in the absence of wind. Sound quality was rated as “moderate” for both audio processors.
Conclusions: The different MD settings of the SONNETeas can provide EAS users with better speech perception compared to an omnidirectional microphone. Concerning speech perception in quiet and quality of life, the performance of the DUET 2 and SONNETeas audio processors was comparable.
Acinetobacter baumannii is a Gram-negative pathogen that causes a multitude of nosocomial infections. The Acinetobacter trimeric autotransporter adhesin (Ata) belongs to the superfamily of trimeric autotransporter adhesins which are important virulence factors in many Gram-negative species. Phylogenetic profiling revealed that ata is present in 78% of all sequenced A. baumannii isolates but only in 2% of the closely related species A. calcoaceticus and A. pittii. Employing a markerless ata deletion mutant of A. baumannii ATCC 19606 we show that adhesion to and invasion into human endothelial and epithelial cells depend on Ata. Infection of primary human umbilical cord vein endothelial cells (HUVECs) with A. baumannii led to the secretion of interleukin (IL)-6 and IL-8 in a time- and Ata-dependent manner. Furthermore, infection of HUVECs by WT A. baumannii was associated with higher rates of apoptosis via activation of caspases-3 and caspase-7, but not necrosis, in comparison to ∆ata. Ata deletion mutants were furthermore attenuated in their ability to kill larvae of Galleria mellonella and to survive in larvae when injected at sublethal doses. This indicates that Ata is an important multifunctional virulence factor in A. baumannii that mediates adhesion and invasion, induces apoptosis and contributes to pathogenicity in vivo.
Heart valve disease is a major clinical problem worldwide. Cardiac valve development and homeostasis need to be precisely controlled. Hippo signaling is essential for organ development and tissue homeostasis, while its role in valve formation and morphology maintenance remains unknown. VGLL4 is a transcription cofactor in vertebrates and we found it was mainly expressed in valve interstitial cells at the post-EMT stage and was maintained till the adult stage. Tissue specific knockout of VGLL4 in different cell lineages revealed that only loss of VGLL4 in endothelial cell lineage led to valve malformation with expanded expression of YAP targets. We further semi-knockout YAP in VGLL4 ablated hearts, and found hyper proliferation of arterial valve interstitial cells was significantly constrained. These findings suggest that VGLL4 is important for valve development and manipulation of Hippo components would be a potential therapy for preventing the progression of congenital valve disease.
Background: Pulmonary nocardiosis (PN) is an uncommon but potentially life-threatening infection. Most of our knowledge is derived from case reports or smaller case series. Recently, increasing PN incidence rates have been reported. We aim to describe the clinical course of and risk factors for PN in four Western European countries and to estimate population-based annual hospitalization rates.
Methods: Retrospective evaluation (1995 to 2011) of the clinical course of and risk factors for PN in patients from 11 hospitals in four European countries (Germany, Austria, Switzerland and The Netherlands). Calculation of population-based estimates of hospitalization rates of PN in Germany (2005 to 2011) using official German nationwide diagnosis-related groups (DRG) hospital statistics.
Results: Forty-three patients fulfilled stringent criteria for proven (n = 8) and probable (n = 35) PN; seven with extrapulmonary dissemination. Within the 43 patients, major PN risk factors were immunocompromising (83.7%) and/or pulmonary (58.1%; in 27.9% as only comorbidity) comorbidities. Median duration of PN targeted therapy was 12 weeks. Distinguished patterns of resistance were observed (imipenem susceptibility: N. farcinica 33.3%; N. asteroides 66.7%). Overall mortality rate was 18.9%; in disseminated PN 50%. Over time, annual PN hospitalization rates remained unchanged at around 0.04/100′000 with the highest rate among men aged 75–84 years (0.24/100′000).
Conclusion: PN is rare, but potentially life-threatening, and mainly affects immunocompromised elder males. Overall annual hospitalization rates remained stable between 2005 and 2011.
Objective: Inhaled particulate matter (PM) in secondhand smoke (SHS) is deleterious for smokers and non-smokers. Different additives in cigarettes might effect the amount of PM. This study aimed to assess the influence of additives on the PM emissions from different cigarette types in SHS.
Design: An experimental study of PM measuring in SHS of cigarettes without exposition of any person.
Method: The concentrations of PM (PM10, PM2.5 and PM1) in SHS of four different types of cigarettes of the brand Lucky Strike, two types with additives (Original Red, Original Blue) and two types without additives (Straight Red, Straight Blue), in comparison to the reference cigarette 3R4F were analysed. An automatic environmental tobacco smoke emitter generated SHS in an enclosed space with a volume of 2.88 m3. PM was measured with a laser aerosol spectrometer (Grimm model 1.109). Afterwards, the measuring values of the four Lucky Strike brands and the reference cigarette were statistically evaluated and visualised.
Results: Lucky Strike Straight Blue, a cigarette type without additives and lower tar amount, showed 10% to 25% lower PM mean values compared with the other tested Lucky Strike products, but 21% (PM1) respectively 27% (PM2.5,PM10) higher mean values than the reference cigarette. The PM mean of all measured smoke-free baseline values (clean air) was 1.6 µg/m³. It increased up to about 1800 µg/m³ for the reference cigarette and up to about 3070 µg/m³ for the Lucky Strike Original Blue.
Conclusions: The findings of this study show the massive increase of PM amount by smoking cigarettes in enclosed spaces and suggest that additives in tobacco products increase the PM amount in SHS. For validation, further comparative studies are necessary focusing on the comparison of the PM concentration of cigarettes with and without additives.
Implications: Due to the exposure to SHS, 890 000 people die each year worldwide. PM in SHS endangers the health of both non-smokers and smokers. This study considers the effect of additives like aromatics and humectant agents in cigarettes on PM in SHS. Do additives in tobacco products increase the amount of PM?
The hepatitis C virus (HCV) RNA replication cycle is a dynamic intracellular process occurring in three-dimensional space (3D), which is difficult both to capture experimentally and to visualize conceptually. HCV-generated replication factories are housed within virus-induced intracellular structures termed membranous webs (MW), which are derived from the Endoplasmatic Reticulum (ER). Recently, we published 3D spatiotemporal resolved diffusion–reaction models of the HCV RNA replication cycle by means of surface partial differential equation (sPDE) descriptions. We distinguished between the basic components of the HCV RNA replication cycle, namely HCV RNA, non-structural viral proteins (NSPs), and a host factor. In particular, we evaluated the sPDE models upon realistic reconstructed intracellular compartments (ER/MW). In this paper, we propose a significant extension of the model based upon two additional parameters: different aggregate states of HCV RNA and NSPs, and population dynamics inspired diffusion and reaction coefficients instead of multilinear ones. The combination of both aspects enables realistic modeling of viral replication at all scales. Specifically, we describe a replication complex state consisting of HCV RNA together with a defined amount of NSPs. As a result of the combination of spatial resolution and different aggregate states, the new model mimics a cis requirement for HCV RNA replication. We used heuristic parameters for our simulations, which were run only on a subsection of the ER. Nevertheless, this was sufficient to allow the fitting of core aspects of virus reproduction, at least qualitatively. Our findings should help stimulate new model approaches and experimental directions for virology.
Spirochetes belonging to the Borrelia (B.) burgdorferi sensu lato (s.l.) complex differ in their ability to establish infection and to survive in diverse vertebrate hosts. Association with and adaption to various hosts most likely correlates with the spirochetes' ability to acquire complement regulator factor H (FH) to overcome the host's innate immune response. Here we assessed binding of serum FH from human and various animals including bovine, cat, chicken, dog, horse, mouse, rabbit, and rat to viable B. burgdorferi sensu stricto (s.s.), B. afzelii, B. garinii, B. spielmanii, B. valaisiana, and B. lusitaniae. Spirochetes ectopically producing CspA orthologs of B. burgdorferi s.s., B. afzelii, and B. spielmanii, CspZ, ErpC, and ErpP, respectively, were also investigated. Our comparative analysis using viable bacterial cells revealed a striking heterogeneity among Lyme disease spirochetes regarding their FH-binding patterns that almost mirrors the serum susceptibility of the respective borrelial genospecies. Moreover, native CspA from B. burgdorferi s.s., B. afzelii, and B. spielmanii as well as CspZ were identified as key ligands of FH from human, horse, and rat origin while ErpP appears to bind dog and mouse FH and to a lesser extent human FH. By contrast, ErpC did not bind FH from human as well as from animal origin. These findings indicate a strong restriction of distinct borrelial proteins toward binding of polymorphic FH of various vertebrate hosts.
Introduction: Merkel cell carcinoma (MCC) is linked to the presence of clonally integrated Merkel cell polyomavirus (MCPyV) in up to 80% of the cases. The aim of the study was to determine the prognostic value of baseline MCPyV viral load and lymphocytic infiltration.
Methods: MCPyV DNA prevalence, integration status and viral load were determined by specific quantitative real-time PCR in surgical specimens obtained from 49 patients with MCC treated with (n = 22, 45%) or without postoperative radiotherapy (RT). CD8+ tumor infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) status were assessed using immunohistochemistry. MCPyV characteristics and immune marker expression were correlated with clinicopathological factors and overall survival (OS).
Results: Median age at diagnosis was 74 (range, 42–100); 51% of the patients were female. One-, three, and five-year OS rates were 83.8, 58.6, and 47.1%, respectively. A positive MCPyV status was associated with female gender (p = 0.042). Tumor localization (head/arms vs. trunk) positively correlated with PD-L1 status (p = 0.011) and combined CD8/PD-L1 expression (p = 0.038). Overall CD8+ infiltration was inversely associated with N-stage (p = 0.048). Stromal TILs correlated significantly with both PD-L1 expression (p = 0.010) and N-stage (p = 0.037). A high viral load (>median) was significantly associated with worse OS (p = 0.029) and high intratumoral CD8+ infiltration with improved OS for the entire cohort (p = 0.045).
Conclusion: These data provide important insight on the role of MCPy DNA viral load and TILs in the context of PD-L1 in patients with Merkel cell carcinoma. Future clinical studies should aim to explore the effect of PD-1/PD-L1 immune-checkpoint inhibitors in combination with existing radiotherapy approaches.
The optimal treatment strategy for secondary prevention in patients with cryptogenic stroke and patent foramen ovale (PFO) has been a matter of controversy for decades. After three randomized trials failed to show a benefit of closure with an excess of complications in the interventional arm, two large recent trials suggest a benefit with regard of preventing further ischemic strokes. With this discrepancy in results it is important to discuss recent trials in detail and evolve an informed clinical approach for daily practice.
Background: Perioperative anaemia leads to impaired oxygen supply with a risk of vital organ ischaemia. In healthy and fit individuals, anaemia can be compensated by several mechanisms. Elderly patients, however, have less compensatory mechanisms because of multiple co-morbidities and age-related decline of functional reserves. The purpose of the study is to evaluate whether elderly surgical patients may benefit from a liberal red blood cell (RBC) transfusion strategy compared to a restrictive transfusion strategy.
Methods: The LIBERAL Trial is a prospective, randomized, multicentre, controlled clinical phase IV trial randomising 2470 elderly (≥ 70 years) patients undergoing intermediate- or high-risk non-cardiac surgery. Registered patients will be randomised only if Haemoglobin (Hb) reaches ≤9 g/dl during surgery or within 3 days after surgery either to the LIBERAL group (transfusion of a single RBC unit when Hb ≤ 9 g/dl with a target range for the post-transfusion Hb level of 9–10.5 g/dl) or the RESTRICTIVE group (transfusion of a single RBC unit when Hb ≤ 7.5 g/dl with a target range for the post-transfusion Hb level of 7.5–9 g/dl). The intervention per patient will be followed until hospital discharge or up to 30 days after surgery, whichever occurs first. The primary efficacy outcome is defined as a composite of all-cause mortality, acute myocardial infarction, acute ischaemic stroke, acute kidney injury (stage III), acute mesenteric ischaemia and acute peripheral vascular ischaemia within 90 days after surgery. Infections requiring iv antibiotics with re-hospitalisation are assessed as important secondary endpoint. The primary endpoint will be analysed by logistic regression adjusting for age, cancer surgery (y/n), type of surgery (intermediate- or high-risk), and incorporating centres as random effect.
Discussion: The LIBERAL-Trial will evaluate whether a liberal transfusion strategy reduces the occurrence of major adverse events after non-cardiac surgery in the geriatric population compared to a restrictive strategy within 90 days after surgery.
Trial registration: ClinicalTrials.gov (identifier: NCT03369210).
Preclinical studies point to a pivotal role of the orexin 1 (OX1) receptor in arousal and fear learning and therefore suggest the HCRTR1 gene as a prime candidate in panic disorder (PD) with/without agoraphobia (AG), PD/AG treatment response, and PD/AG-related intermediate phenotypes. Here, a multilevel approach was applied to test the non-synonymous HCRTR1 C/T Ile408Val gene variant (rs2271933) for association with PD/AG in two independent case-control samples (total n = 613 cases, 1839 healthy subjects), as an outcome predictor of a six-weeks exposure-based cognitive behavioral therapy (CBT) in PD/AG patients (n = 189), as well as with respect to agoraphobic cognitions (ACQ) (n = 483 patients, n = 2382 healthy subjects), fMRI alerting network activation in healthy subjects (n = 94), and a behavioral avoidance task in PD/AG pre- and post-CBT (n = 271). The HCRTR1 rs2271933 T allele was associated with PD/AG in both samples independently, and in their meta-analysis (p = 4.2 × 10−7), particularly in the female subsample (p = 9.8 × 10−9). T allele carriers displayed a significantly poorer CBT outcome (e.g., Hamilton anxiety rating scale: p = 7.5 × 10−4). The T allele count was linked to higher ACQ sores in PD/AG and healthy subjects, decreased inferior frontal gyrus and increased locus coeruleus activation in the alerting network. Finally, the T allele count was associated with increased pre-CBT exposure avoidance and autonomic arousal as well as decreased post-CBT improvement. In sum, the present results provide converging evidence for an involvement of HCRTR1 gene variation in the etiology of PD/AG and PD/AG-related traits as well as treatment response to CBT, supporting future therapeutic approaches targeting the orexin-related arousal system.
The IPS e.max system by Ivoclar Vivadent, offering a variety of products and indications, is widely used for all-ceramic restorations. We analyzed the clinical track record of these products in daily clinical practice, associating their restorative survival rate with various parameters to define recommendations for long-term stability. A total of 1058 full-coverage crowns and fixed partial dentures (FPDs) were evaluated retrospectively over up to 66.48 (37.05 ± 18.4) months. All were made of IPS e.max Press, IPS e.max CAD, IPS e.max Ceram or IPS e.max ZirPress and had been delivered by a private dental practice within three years. Uses not recommended by the manufacturer were also deliberately included. The five-year cumulative survival was 94.22% (i.e., 94.69% or 90.58% for glass-ceramic crowns or FDPs and 100% or 90.06% for zirconia-based crowns or FDPs). Significantly superior outcomes emerged for conventional vs. adhesive cementation and for vital vs. non-vital abutment teeth, but not for recommended vs. non-recommended uses. Caution is required in restoring non-vital teeth, but the spectrum of recommended uses should generally be reconsidered and expanded, given our finding of high survival and success rates for IPS e.max ceramics, even for uses not currently recommended by the manufacturer.
A novel osteotomy preparation technique to preserve implant site viability and enhance osteogenesis
(2019)
The preservation of bone viability at an osteotomy site is a critical variable for subsequent implant osseointegration. Recent biomechanical studies evaluating the consequences of site preparation led us to rethink the design of bone-cutting drills, especially those intended for implant site preparation. We present here a novel drill design that is designed to efficiently cut bone at a very low rotational velocity, obviating the need for irrigation as a coolant. The low-speed cutting produces little heat and, consequently, osteocyte viability is maintained. The lack of irrigation, coupled with the unique design of the cutting flutes, channels into the osteotomy autologous bone chips and osseous coagulum that have inherent osteogenic potential. Collectively, these features result in robust, new bone formation at rates significantly faster than those observed with conventional drilling protocols. These preclinical data have practical implications for the clinical preparation of osteotomies and alveolar bone reconstructive surgeries.
Background: Preclinical studies demonstrate synergism between cancer immunotherapy and local radiation, enhancing anti-tumor effects and promoting immune responses. BI1361849 (CV9202) is an active cancer immunotherapeutic comprising protamine-formulated, sequence-optimized mRNA encoding six non-small cell lung cancer (NSCLC)-associated antigens (NY-ESO-1, MAGE-C1, MAGE-C2, survivin, 5T4, and MUC-1), intended to induce targeted immune responses.
Methods: We describe a phase Ib clinical trial evaluating treatment with BI1361849 combined with local radiation in 26 stage IV NSCLC patients with partial response (PR)/stable disease (SD) after standard first-line therapy. Patients were stratified into three strata (1: non-squamous NSCLC, no epidermal growth factor receptor (EGFR) mutation, PR/SD after ≥4 cycles of platinum- and pemetrexed-based treatment [n = 16]; 2: squamous NSCLC, PR/SD after ≥4 cycles of platinum-based and non-platinum compound treatment [n = 8]; 3: non-squamous NSCLC, EGFR mutation, PR/SD after ≥3 and ≤ 6 months EGFR-tyrosine kinase inhibitor (TKI) treatment [n = 2]). Patients received intradermal BI1361849, local radiation (4 × 5 Gy), then BI1361849 until disease progression. Strata 1 and 3 also had maintenance pemetrexed or continued EGFR-TKI therapy, respectively. The primary endpoint was evaluation of safety; secondary objectives included assessment of clinical efficacy (every 6 weeks during treatment) and of immune response (on Days 1 [baseline], 19 and 61).
Results: Study treatment was well tolerated; injection site reactions and flu-like symptoms were the most common BI1361849-related adverse events. Three patients had grade 3 BI1361849-related adverse events (fatigue, pyrexia); there was one grade 3 radiation-related event (dysphagia). In comparison to baseline, immunomonitoring revealed increased BI1361849 antigen-specific immune responses in the majority of patients (84%), whereby antigen-specific antibody levels were increased in 80% and functional T cells in 40% of patients, and involvement of multiple antigen specificities was evident in 52% of patients. One patient had a partial response in combination with pemetrexed maintenance, and 46.2% achieved stable disease as best overall response. Best overall response was SD in 57.7% for target lesions.
Conclusion: The results support further investigation of mRNA-based immunotherapy in NSCLC including combinations with immune checkpoint inhibitors.
Trial registration: ClinicalTrials.gov identifier: NCT01915524.
Iron is an essential element for virtually all organisms. On the one hand, it facilitates cell proliferation and growth. On the other hand, iron may be detrimental due to its redox abilities, thereby contributing to free radical formation, which in turn may provoke oxidative stress and DNA damage. Iron also plays a crucial role in tumor progression and metastasis due to its major function in tumor cell survival and reprogramming of the tumor microenvironment. Therefore, pathways of iron acquisition, export, and storage are often perturbed in cancers, suggesting that targeting iron metabolic pathways might represent opportunities towards innovative approaches in cancer treatment. Recent evidence points to a crucial role of tumor-associated macrophages (TAMs) as a source of iron within the tumor microenvironment, implying that specifically targeting the TAM iron pool might add to the efficacy of tumor therapy. Here, we provide a brief summary of tumor cell iron metabolism and updated molecular mechanisms that regulate cellular and systemic iron homeostasis with regard to the development of cancer. Since iron adds to shaping major hallmarks of cancer, we emphasize innovative therapeutic strategies to address the iron pool of tumor cells or cells of the tumor microenvironment for the treatment of cancer.
Background: With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clinical practice. This study primarily aimed to describe the time to treatment failure (TTF) of mCRPC patients treated with abiraterone acetate plus prednisone or the corticosteroid of choice (AAP) in the pre-chemotherapy setting. Other relevant outcomes, clinical and treatment characteristics of these patients were also evaluated.
Methods: This retrospective, observational study collected data from chemotherapy-naïve mCRPC patients treated with AAP from four European countries. Kaplan-Meier curves were used to estimate TTF, progression-free survival (PFS), and time to first skeletal-related event. The impact of baseline characteristics on TTF and PFS was explored using univariate and multivariate Cox proportional hazard models. Log-rank test was used to assess the potential role of duration of response to ADT in predicting response to AAP treatment.
Results: Data from 481 eligible patients (Belgium: 68; France: 61; Germany: 150; UK: 202) were analysed. At AAP initiation, the median age of patients was 75.0 years (interquartile range [IQR]: 69.0–81.0), and the median PSA was 56.2 ng/mL (IQR: 22.2–133.1), with over 50% of patients presenting an ECOG score of 0 or 1. Visceral metastases were present in 7.5% of patients; an exclusion criterion in the COU-AA-302 clinical trial. The median TTF with AAP was 10.0 months (95%CI: 9.2–11.1) and the median PFS was 10.8 months (95%CI: 9.6–11.8). Shorter TTF was significantly associated with higher ALP (> 119 units/L), higher PSA (> 56.2 ng/mL), or poorer ECOG PS scores at AAP initiation (p < 0.05). Patients with longer duration of response to ADT (≥12 months) presented longer TTF and longer time to progression (p < 0.0001).
Conclusions: This European real-world study provides valuable insights into the characteristics, treatment, and outcomes of chemotherapy-naïve patients with mCRPC who received AAP in routine clinical practice. Treatment effectiveness of AAP in the real-world is maintained despite patients having poorer clinical features at initiation than those observed in the COU-AA-302 trial population.
Background: To evaluate optimal therapy and potential risk factors.
Methods: Data of DSRCT patients <40 years treated in prospective CWS trials 1997‐2015 were analyzed.
Results: Median age of 60 patients was 14.5 years. Male:female ratio was 4:1. Tumors were abdominal/retroperitoneal in 56/60 (93%). 6/60 (10%) presented with a localized mass, 16/60 (27%) regionally disseminated nodes, and 38/60 (63%) with extraperitoneal metastases. At diagnosis, 23/60 (38%) patients had effusions, 4/60 (7%) a thrombosis, and 37/54 (69%) elevated CRP. 40/60 (67%) patients underwent tumor resection, 21/60 (35%) macroscopically complete. 37/60 (62%) received chemotherapy according to CEVAIE (ifosfamide, vincristine, actinomycin D, carboplatin, epirubicin, etoposide), 15/60 (25%) VAIA (ifosfamide, vincristine, adriamycin, actinomycin D) and, 5/60 (8%) P6 (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide). Nine received high‐dose chemotherapy, 6 received regional hyperthermia, and 20 received radiotherapy. Among 25 patients achieving complete remission, 18 (72%) received metronomic therapies. Three‐year event‐free (EFS) and overall survival (OS) were 11% (±8 confidence interval [CI] 95%) and 30% (±12 CI 95%), respectively, for all patients and 26.7% (±18.0 CI 95%) and 56.9% (±20.4 CI 95%) for 25 patients achieving remission. Extra‐abdominal site, localized disease, no effusion or ascites only, absence of thrombosis, normal CRP, complete tumor resection, and chemotherapy with VAIA correlated with EFS in univariate analysis. In multivariate analysis, significant factors were no thrombosis and chemotherapy with VAIA. In patients achieving complete remission, metronomic therapy with cyclophosphamide/vinblastine correlated with prolonged time to relapse.
Conclusion: Pleural effusions, venous thrombosis, and CRP elevation were identified as potential risk factors. The VAIA scheme showed best outcome. Maintenance therapy should be investigated further.
Background: Liver cirrhosis is associated with profound immunodysfunction, i.e. a parallel presence of chronic systemic inflammation and immunosuppression, which can result in acute-on-chronic liver failure (ACLF). Omega-3 fatty acids are precursors of pro-resolving mediators and support the resolution of inflammation.
Objective: The aim of this study was to determine plasma levels of omega-3 fatty acids in patients with liver cirrhosis and ACLF.
Methods: Patients with liver cirrhosis with and without ACLF were enrolled in a prospective cohort study and analyzed post-hoc for the present sub-study. Clinical data and biomaterials were collected at baseline and at day 7, 28 and after 3 months of follow-up. Plasma concentrations of arachidonic acid (ARA) and docosahexaenoic acid (DHA), which represent key omega-6 and -3 fatty acids, respectively, were quantified and associated with markers of systemic inflammation and severity of liver cirrhosis.
Results: A total of 117 patients were included in the present analyses. Of those, 26 (22.2%), 51 (43.6%) and 40 (34.2%) patients had compensated or decompensated liver cirrhosis, and ACLF. Plasma levels of ARA and DHA were similar in patients with compensated cirrhosis, decompensated cirrhosis, and ACLF. Furthermore, no significant association between plasma ARA or DHA and C-reactive protein or peripheral blood leukocytes were observed (P>0.05).
Conclusion: In our study plasma levels of key omega-3 and omega-6 fatty acid are neither associated with the severity of liver cirrhosis nor with liver-cirrhosis-associated systemic inflammation.
In many countries a majority of cancer patients are not treated at Comprehensive Cancer Centers (CCCs). Even for those that are, parts of the treatment or follow‐up may be carried out in local community hospitals or in private practices. How to assure quality in cancer care and create innovation? How to integrate decentralized versus centralized patient care, education, and cancer research? Outlined here is a 360° view of outreach to include all stake holders – most importantly patients and their families, patient advocacy groups, health care providers, health insurers, and policy makers.
Endothelial to mesenchymal transition in cardiovascular disease : JACC state-of-the-art review
(2019)
Endothelial to mesenchymal transition (EndMT) is a process whereby an endothelial cell undergoes a series of molecular events that lead to a change in phenotype toward a mesenchymal cell (e.g., myofibroblast, smooth muscle cell). EndMT plays a fundamental role during development, and mounting evidence indicates that EndMT is involved in adult cardiovascular diseases (CVDs), including atherosclerosis, pulmonary hypertension, valvular disease, and fibroelastosis. Therefore, the targeting of EndMT may hold therapeutic promise for treating CVD. However, the field faces a number of challenges, including the lack of a precise functional and molecular definition, a lack of understanding of the causative pathological role of EndMT in CVDs (versus being a “bystander-phenomenon”), and a lack of robust human data corroborating the extent and causality of EndMT in adult CVDs. Here, we review this emerging but exciting field, and propose a framework for its systematic advancement at the molecular and translational levels.
Sepsis is characterized by dysregulated gene expression, provoking a hyper-inflammatory response occurring in parallel to a hypo-inflammatory reaction. This is often associated with multi-organ failure, leading to the patient’s death. Therefore, reprogramming of these pro- and anti-inflammatory, as well as immune-response genes which are involved in acute systemic inflammation, is a therapy approach to prevent organ failure and to improve sepsis outcomes. Considering epigenetic, i.e., reversible, modifications of chromatin, not altering the DNA sequence as one tool to adapt the expression profile, inhibition of factors mediating these changes is important. Acetylation of histones by histone acetyltransferases (HATs) and initiating an open-chromatin structure leading to its active transcription is counteracted by histone deacetylases (HDACs). Histone deacetylation triggers a compact nucleosome structure preventing active transcription. Hence, inhibiting the activity of HDACs by specific inhibitors can be used to restore the expression profile of the cells. It can be assumed that HDAC inhibitors will reduce the expression of pro-, as well as anti-inflammatory mediators, which blocks sepsis progression. However, decreased cytokine expression might also be unfavorable, because it can be associated with decreased bacterial clearance.
Introduction: The global spread of multidrug-resistant organisms (MDRO) complicates treatment and isolation measures in hospitals and has shown to increase mortality. Patients with disease- or therapy-related immunodeficiency are especially at risk for fatal infections caused by MDRO. The impact of MDRO colonization on the clinical course of AML patients undergoing intensive induction chemotherapy—a potentially curative but highly toxic treatment option—has not been systematically studied.
Materials & methods: 312 AML patients undergoing intensive induction chemotherapy between 2007 and 2015 were examined for MDRO colonization. Patients with evidence for MDRO before or during the hospital stay of induction chemotherapy were defined as colonized, patients who never had a positive swab for MDRO were defined as noncolonized.
Results: Of 312 AML patients 90 were colonized and 130 were noncolonized. Colonized patients suffered from significantly more days with fever, spent more days on the intensive care unit and had a higher median C-reactive protein value during the hospital stay. These findings did not result in a prolonged length of hospital stay or an increased mortality rate for colonized patients. However, in a subgroup analysis, patients colonized with carbapenem-resistant enterobacteriaceae (CRE) had a significantly reduced 60- and 90-day, as well as 1- and 2-year survival rates when compared to noncolonized patients.
Conclusion: Our analysis highlights the importance of intensive MDRO screening especially in patients with febrile neutropenia since persisting fever can be a sign of MDRO-colonization. CRE-colonized patients require special surveillance, since they seem to be at risk for death.
The inhalation of particulate matter (PM) in second-hand smoke (SHS) is hazardous to health of smokers and non-smokers. Tobacco strength (amount of tar, nicotine, and carbon monoxide) and different additives might have an effect on the amount of PM. This study aimed to investigate the influence of tobacco strength or additives on PM. Four cigarette types of the brand Marlboro with different strengths and with or without additives were analyzed in comparison to the 3R4F reference cigarette. SHS was generated by an automatic environmental tobacco smoke emitter (AETSE) in an enclosed space with a volume of 2.88 m³. PM concentrations (PM10, PM2.5, PM1) were measured with a laser aerosol spectrometer followed by statistical analysis. The two strongest Marlboro brands (Red and Red without additives) showed the highest PM concentrations of all tested cigarettes. The measured mean concentrations Cmean of PM10 increased up to 1458 µg/m³ for the Marlboro Red without additives (PM2.5: 1452 µg/m³, PM1: 1263 µg/m³). The similarly strong Marlboro Red showed very similar PM values. The second strongest type Marlboro Gold showed 36% (PM10, PM2.5) and 32% (PM1) lower values, respectively. The “lightest” type Marlboro Silver Blue showed 54% (PM10, PM2.5) or 50% (PM1) lower PM values. The results indicate that the lower the tar, nicotine, and carbon monoxide amounts, as well as the longer the cigarette filter, the lower are the PM levels. An influence of additives could not be determined.
During erythropoiesis, haematopoietic stem cells (HSCs) differentiate in successive steps of commitment and specification to mature erythrocytes. This differentiation process is controlled by transcription factors that establish stage- and cell type-specific gene expression. In this study, we demonstrate that FUSE binding protein 1 (FUBP1), a transcriptional regulator important for HSC self-renewal and survival, is regulated by T-cell acute lymphocytic leukaemia 1 (TAL1) in erythroid progenitor cells. TAL1 directly activates the FUBP1 promoter, leading to increased FUBP1 expression during erythroid differentiation. The binding of TAL1 to the FUBP1 promoter is highly dependent on an intact GATA sequence in a combined E-box/GATA motif. We found that FUBP1 expression is required for efficient erythropoiesis, as FUBP1-deficient progenitor cells were limited in their potential of erythroid differentiation. Thus, the finding of an interconnection between GATA1/TAL1 and FUBP1 reveals a molecular mechanism that is part of the switch from progenitor- to erythrocyte-specific gene expression. In summary, we identified a TAL1/FUBP1 transcriptional relationship, whose physiological function in haematopoiesis is connected to proper erythropoiesis.
Introduction: Epoxyeicosatrienoic acids (EETs) are able to enhance angiogenesis and regulate inflammation that is especially important in wound healing under ischemic conditions. Thus, we evaluated the effect of local EET application on ischemic wounds in mice.
Methods: Ischemia was induced by cautherization of two of the three supplying vessels to the mouse ear. Wounding was performed on the ear three days later. Wounds were treated either with 11,12 or 14,15 EET and compared to untreated control and normal wounds. Epithelialization was measured every second day. VEGF, TNF-α, TGF-β, matrix metalloproteinases (MMP), tissue inhibitors of metalloproteinases (TIMP), Ki67, and SDF-1α were evaluated immunohistochemically in wounds on day 3, 6, and 9.
Results: Ischemia delayed wound closure (12.8 days ± 1.9 standard deviation (SD) for ischemia and 8.0 days ± 0.94 SD for control). 11,12 and14,15 EET application ameliorated deteriorated wound healing on ischemic ears (7.6 ± 1.3 SD for 11,12 EET and 9.2 ± 1.4 SD for 14,15 EET). Ischemia did not change VEGF, TNF-α, TGF-β, SDF-1α, TIMP, MMP7 or MMP9 level significantly compared to control. Local application of 11,12 as well as 14,15 EET induced a significant elevation of VEGF, TGF-β, and SDF-1α expression as well as proliferation during the whole phase of wound healing compared to control and ischemia alone.
Conclusion: In summary, EET improve impaired wound healing caused by ischemia as they enhance neovascularization and alter inflammatory response in wounds. Thus elevating lipid mediator level as 11,12 and 14,15 EET in wounds might be a successful strategy for amelioration of deranged wound healing under ischemia.
The current Special Issue is devoted to the broad spectrum of hepatotoxicity with its molecular mechanisms and pathophysiology, presented in eight publications. Scientists were from various countries, including the US, Mexico, the Czech Republic, Germany, Portugal, China, and Japan. Contributions considered various types of experimental and human liver injury, elicited by a number of causal conditions and substances. ...
Background: Hepatitis B (HepB) is a major public health concern in Malaysia yet little is known about knowledge and awareness of this infection in the country. Such information is essential for designing effective intervention strategies for HepB prevention and control. The aim of this study was to characterize knowledge and awareness regarding HepB in Malaysia and to identify their associated sociodemographic determinants.
Methods: A community-based cross-sectional survey was conducted between January and May 2016 in Selangor state of Malaysia. A two-stage cluster random sampling design was used and one adult member of selected households was interviewed face-to-face. Logistic regression was used to estimate the differences in knowledge and awareness between groups.
Results: A total of 764 households completed the interviews and were included in the final analysis. Only 36.9 and 38.8% of the participants had good knowledge and awareness, respectively. The factors associated with good knowledge were being in the 35–44 year age group, Malay ethnicity, high educational attainment and high family income. Being Chinese, being older and having high educational attainment were determinants of having good awareness towards HepB. Participants who had good knowledge were 2.5 times more likely to also have good awareness (OR: 2.41, 95% CI: 1.78–3.26, p < 0.001).
Conclusions: This study reveals a low level of knowledge and awareness of HepB among households in Malaysia. This finding highlights the need to improve public knowledge and awareness through well-designed programs targeting vulnerable groups in order to reduce hepatitis B virus transmission and achieve the governmental target of eliminating viral hepatitis as a public health concern by 2030.
Background: Arthropod-borne diseases remain a major health-threat for humans and animals worldwide. To estimate the distribution of pathogenic agents and especially Bartonella spp., we conducted tick microbiome analysis and determination of the infection status of wild animals, pets and pet owners in the state of Hesse, Germany.
Results: In total, 189 engorged ticks collected from 163 animals were tested. Selected ticks were analyzed by next generation sequencing (NGS) and confirmatory PCRs, blood specimens of 48 wild animals were analyzed by PCR to confirm pathogen presence and sera of 54 dogs, one cat and 11 dog owners were analyzed by serology. Bartonella spp. were detected in 9.5% of all ticks and in the blood of 17 roe deer. Further data reveal the presence of the human and animal pathogenic species of genera in the family Spirochaetaceae (including Borrelia miyamotoi and Borrelia garinii), Bartonella spp. (mainly Bartonella schoenbuchensis), Rickettsia helvetica, Francisella tularensis and Anaplasma phagocytophilum in ticks. Co-infections with species of several genera were detected in nine ticks. One dog and five dog owners were seropositive for anti-Bartonella henselae-antibodies and one dog had antibodies against Rickettsia conorii.
Conclusions: This study provides a snapshot of pathogens circulating in ticks in central Germany. A broad range of tick-borne pathogens are present in ticks, and especially in wild animals, with possible implications for animal and human health. However, a low incidence of Bartonella spp., especially Bartonella henselae, was detected. The high number of various detected pathogens suggests that ticks might serve as an excellent sentinel to detect and monitor zoonotic human pathogens.
Purpose: To examine whether applying case management in general practices reduces thromboembolic events requiring hospitalization and major bleeding events (combined primary outcome). Secondary endpoints were mortality, frequency and duration of hospitalization, severe treatment interactions, adverse events, quality of anticoagulation, health-related quality of life and intervention costs, patients’ assessment of chronic illness care, self-reported adherence to medication, GP and HCA knowledge, patient knowledge and satisfaction with shared decision-making.
Methods: Cluster-randomized controlled trial undertaken at 52 general practices in Germany with adult patients with a long-term indication for oral anticoagulation. The complex intervention included training for healthcare assistants, information and quality circles for general practitioners and 24 months of case management for patients. Assessment was after 12 and 24 months. The intention-to-treat population included all randomized practices and patients, while the per-protocol analysis included only those that received treatment without major protocol violations.
Results: The mean (SD) age of the 736 patients was 73.5 (9.4) years and 597 (81.1%) had atrial fibrillation. After 24 months, the primary endpoint had occurred in 40 (11.0%) intervention and 48 (12.9%) control patients (hazard ratio 0.83, 95% CI 0.55 to 1.25; P = .37). Patients’ perceived quality of care, their knowledge, and HCAs’ knowledge, had improved significantly at 24 months. The other secondary endpoints did not differ between groups. In the intervention group, hospital admissions were significantly reduced in patients that received treatment without major protocol deviations.
Conclusions: Even though the main outcomes did not differ significantly, the intervention appears to have positively influenced several process parameters under "real-world conditions".
While aberrant cells are routinely recognized and removed by immune cells, tumors eventually escape innate immune responses. Infiltrating immune cells are even corrupted by the tumor to acquire a tumor-supporting phenotype. In line, tumor-associated macrophages are well-characterized to promote tumor progression and high levels of tumor-infiltrating macrophages are a poor prognostic marker in breast cancer. Here, we aimed to further decipher the influence of macrophages on breast tumor cells and determined global gene expression changes in three-dimensional tumor spheroids upon infiltration of macrophages. While various tumor-associated mRNAs were upregulated, expression of the cytochrome P450 family member CYP1A1 was markedly attenuated. Repression of CYP1A1 in tumor cells was elicited by a macrophage-shaped tumor microenvironment rather than by direct tumor cell-macrophage contacts. In line with changes in RNA expression profiles, macrophages enhanced proliferation of the tumor cells. Enhanced proliferation and macrophage presence further correlated with reduced CYP1A1 expression in patient tumors when compared with normal tissue. These findings are of interest in the context of combinatory therapeutic approaches involving cytotoxic and immune-modulatory compounds.